NewTimeSpace

Hong Kong AI Concept Stock Daily：Tesla Cybercab Officially Launched for Operation, Intelligent Driving Theme Generally Rose-20260904

Fri, 04 Sep 2026 09:51:03 GMT

I. Market Overview

On September 4, 2026, the three major Hong Kong indices opened higher and rebounded, with the Hang Seng Index up 1.74%, the Hang Seng TECH Index up 2.27%, and the Hang Seng China Enterprises Index up 2.02%. The Hang Seng Index's total market turnover was HK$276.9 billion, and southbound funds saw a net outflow of HK$10.021 billion. On that day, the majority of AI concept stocks rose, with the large model and intelligent driving themes mostly strengthening, while AI chips broadly weakened.

In the large model segment, MEITUAN-W (03690.HK) rose 5.28%, Baidu Group-W (09888.HK) rose 4.81%, and MINIMAX-W, ALIBABA-W, KUAISHOU-W, and TENCENT followed the gains. Z.AI (02513.HK) fell 2.98% against the trend.

In the AI chip segment, MONTAGE TECHNOLOGY (06809.HK) rose 1.24%, HUA HONG GRACE (01347.HK) fell 8.43%, and ILUVATAR COREX, SMIC, BIREN TECH, and GIGADEVICE followed the declines.

In the intelligent driving segment, influenced by Tesla Cybercab's official operation, PONY-W (02026.HK) rose 4.05%, and WERIDE-W, ROBOSENSE, and BLACK SESAME followed the gains, while HORIZONROBOT-W (09660.HK) dipped slightly by 0.34%.

In the embodied intelligence segment, XIAOMI-W (01810.HK) closed up 3.64%, and UBTECH ROBOTICS (09880.HK) rose 8.28%.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
09880.HK	UBTECH ROBOTICS	85.650	8.28	Embodied AI
03690.HK	MEITUAN-W	81.750	5.28	LLM
09888.HK	BIDU-SW	95.900	4.81	LLM
02026.HK	PONY-W	57.750	4.05	Autonomous Driving
00800.HK	WERIDE-W	15.980	4.04	Autonomous Driving
02498.HK	ROBOSENSE	18.280	3.92	Autonomous Driving
02533.HK	BLACK SESAME	10.640	3.91	Autonomous Driving
01810.HK	XIAOMI-W	28.440	3.64	Embodied AI
01024.HK	KUAISHOU-W	33.660	2.75	LLM
09988.HK	BABA-SW	110.100	2.42	LLM
00700.HK	TENCENT	442.800	2.26	LLM
00100.HK	MINIMAX-W	361.400	1.80	LLM
06809.HK	MONTAGETECH	261.600	1.24	AI Chips
09660.HK	HORIZONROBOT-W	4.355	-0.34	Autonomous Driving
03986.HK	GIGADEVICE	464.800	-0.43	AI Chips
06082.HK	BIRENTECH	41.600	-1.14	AI Chips
00981.HK	SMIC	67.200	-1.25	AI Chips
02513.HK	Z.AI	1,075.000	-2.98	LLM
09903.HK	ILUVATAR COREX	383.600	-4.62	AI Chips
01347.HK	HUA HONG GRACE	109.700	-8.43	AI Chips

Data Source: HKEX. For reference only, not investment advice. Data as of market close on September 4, 2026.

III. AI Industry & Corporate Developments

1. OpenAI Officially Releases GPT-6 Astra and Declares "Welcome to the AGI Era"

On September 4, OpenAI officially released GPT-6 Astra, calling it "the world's most intelligent and most aligned model to date," having achieved the current state of the art in computer operation, web browsing, software engineering, cybersecurity, scientific research, and professional work. The announcement stated that GPT-6 Astra will first be opened to some enterprises participating in the cybersecurity project Daybreak, and will subsequently be rolled out to all ChatGPT subscription users "in the coming days."

2. Tmall Launches Token Recharge Center, with First Batch Connecting Alibaba Cloud, Z.AI, Kimi, and MiniMax

On September 3, Tmall officially launched the AI Space Station (Token Recharge Center), where users can directly purchase subscription products of multiple leading large models. The page shows that the recharge center aggregates subscription services from leading domestic large model vendors such as Alibaba Cloud, Z.AI, Kimi, and MiniMax. Products on sale include periodically subscribed Token Plans and Coding Plans, as well as usage-based recharge schemes, supporting two delivery methods: card keys or direct recharge.

3. NVIDIA N1X Device to Be Listed in October

News on September 3: NVIDIA (NVDA.US) announced on Thursday that the NVIDIA RTX Spark device will begin shipping in October this year. The core selling point of this computer is precisely NVIDIA's N1X chip. To be able to run AI locally, this chip supports up to 128GB of unified memory, and the Blackwell GPU it carries can provide up to petaflops of floating-point computing power per second.

4. Z.AI GLM-5.3-Flash Launches Limited-Time Free Nighttime Use

Late on September 3, Z.AI announced that from now until September 20, the GLM Coding Plan will launch the "Flash × ZCode" Changdeng campaign. From 23:00 to 9:00 the next day each night, calling the GLM-5.3-Flash included in the plan is free to use within ZCode, and the usage quota is doubled when used in other agents supported by the plan; it takes effect automatically upon entering the designated time period.

5. Tesla Cybercab Officially Launched, Domestic High-Level Autonomous Driving Advances Rapidly

On September 3 local time, Tesla announced that the cyber driverless electric vehicle Cybercab has officially entered operation in Austin, USA. Tesla stated that the model requires no steering wheel, pedals, or rearview mirror, and will undertake more travel demand with higher usage efficiency. Notably, before this launch event, Tesla had already released signals of Cybercab's further scaled operation. It is reported that Tesla's official website has quietly launched an intention registration form, targeting enterprises or individuals interested in purchasing Cybercab fleets.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
MEITUAN-W	03690.HK	AI technology pioneer in local life services	Its AI-native community application “Miyu” has demonstrated operational value in physical retail and dining environments, boosting merchant efficiency. The company continuously enhances search, recommendation, and dispatch algorithms across its local commerce ecosystem using proprietary foundation models. By deploying AI Agent technologies in customer service, merchant marketing assistants, and instant delivery route planning, the company improves dual-sided operational efficiency and management precision.
XIAOMI-W	01810.HK	Full-stack AI technology giant anchored by the "Human x Car x Home" ecosystem	Its foundational model family MiMo has entered the top tier of global open-source models; MiMo-V2-Pro features over 1 trillion parameters, while MiMo-V2.5-Pro tied for 1st globally among open-source models with a score of 54 on the Artificial Analysis composite index. AI capabilities fully power the "Human x Car x Home" ecosystem, driving iterative upgrades in the CyberOne humanoid and CyberDog bionic quadrupeds. Multimodal computer vision, force-control algorithms, and automated dispatch logics are deeply integrated into dark-factory production and flexible manufacturing.
UBTECH ROBOTICS	09880.HK	The purest humanoid robot stock in Hong Kong	The company focuses on humanoid robot R&D, full‑stack motion control algorithms, and commercial deployment across industrial and logistics scenarios. Its flagship Walker S series has been integrated into assembly lines of leading new energy vehicle manufacturers for parts handling, precision assembly, and intelligent quality inspection, pioneering the transition from lab prototypes to industrial automation at scale.
PONY-W	02026.HK	Global commercialization leader in L4 autonomous mobility and logistics	The first autonomous driving company in China to secure fully driverless Robotaxi commercial operation permits across all four top-tier cities (Beijing, Shanghai, Guangzhou, Shenzhen). Core operations span autonomous ride-hailing (Robotaxi) and freight services (Robotruck), with Robotaxi deployments across 9 countries and public operations in overseas markets including Croatia, Qatar, Singapore, and South Korea. Targeting a global fleet exceeding 3,000 vehicles across 20+ cities by 2026, the company has achieved positive unit economics per vehicle.
BIDU-SW	09888.HK	Dual-engine leader in China's AI infrastructure and autonomous driving	Financial results show AI revenue accounting for 52% of core business revenue, replacing traditional advertising as the primary growth driver. Ernie Model 5.1 is officially live, ranking 1st nationally and 4th globally on LMArena benchmarks. The Qianfan model platform aggregates mainstream foundation models for commercial API consumption, driving a 79% YoY surge in AI Cloud revenue. Apollo Go leads in fully driverless commercial operations, accumulating over 330 million operational kilometers and achieving breakeven per vehicle in select cities. Foundation model capabilities continue to penetrate AI Cloud, autonomous driving, and AI-native applications.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Autonomous Driving Concept Stocks Watch | XPENG-W (09868.HK) Trades Firm; Second‑Generation VLA Physical‑World Large Model Sees First Major Iteration

Fri, 04 Sep 2026 07:32:13 GMT

NewTimeSpace News: On September 4, 2026, XPENG-W (09868.HK) traded firmly in the afternoon session. As of 15:15, the stock traded at HK$43.54, up 1.73%.

According to China Business Journal, Xpeng recently held the“TIME”Physical AI Experience Day in Guangzhou. Its second‑generation VLA physical‑world large‑scale model has undergone its first major iteration. The brand‑new XOS 6.3.0 system will make its global debut on the Xpeng G9L.

Jiemian News reported that starting from September 1, multiple Chinese new‑energy vehicle startups released their August 2026 delivery figures. Leapmotor delivered 103,129 vehicles globally, representing an 80.7% year‑on‑year increase; Xpeng Group delivered 39,107 vehicles, up 4% year‑on‑year; Li Auto delivered 37,679 vehicles, a 32.1% year‑on‑year rise; NIO delivered 35,836 vehicles, growing 14.5% year‑on‑year.

XPENG-W (09868.HK) Focuses on the full-stack in-house R&D and large-scale deployment of end-to-end autonomous driving foundational models for mass-produced vehicles. Its proprietary XNGP (Advanced Driver Assistance System) has completely decoupled from high-definition maps, demonstrating exceptional generalization capabilities in complex urban NOA (Navigation Guided Pilot) scenarios. The activation rate of advanced ADAS and the mileage penetration rate among users of newly delivered models remain at the industry forefront, providing a highly deterministic benchmark for vehicle-side AI application delivery.

AI Chip Concept Stocks Watch | Hua Hong Grace (01347.HK) Slumped Sharply, Recently Announced Construction of a Wafer Foundry Line with Planned Monthly Capacity of 55,000 Wafers

Fri, 04 Sep 2026 05:52:38 GMT

NewTimeSpace (newtimespace.com) News, September 4, 2026—The chip theme continued to come under pressure, with Hua Hong Grace (01347.HK) slumping sharply. As of 13:40, the stock was quoted at HK$109.100, down 8.93%.

On the news front, Hua Hong Grace recently announced that the company and its wholly-owned subsidiary, Shanghai Hua Hong Grace Semiconductor Manufacturing Co., Ltd., intend to jointly increase the capital of Wuxi Hua Hong Grace Phase III Semiconductor Co., Ltd. together with three other companies including Wuxi Xihong Guoxin Phase II Investment Co., Ltd., to build a 12-inch specialty-process wafer foundry line with a planned monthly capacity of approximately 55,000 wafers.

Guosheng Securities pointed out that the capabilities of domestic chips have continued to improve, narrowing the generation gap with overseas chips. The adoption of domestic chips by internet and intelligent computing centers has accelerated, and domestic computing power demand is shifting faster toward local manufacturers. The expansion of application scenarios and the accumulation of experience have effectively driven the iterative upgrading of chip capabilities, and a positive R&D feedback loop is gradually taking shape.

HUA HONG GRACE(01347.HK)Specializes in specialty process wafer foundry, offering customized manufacturing of power discretes, embedded non-volatile memory, analog and power management ICs. Its 8-inch and 12-inch production lines serve automotive, industrial control and data center power management applications. The company holds multiple automotive-grade quality certifications and provides mass production foundry services to various domestic and international automotive clients. Its overall capacity utilization has remained high over an extended period.

Humanoid Robot Concept Stocks Watch | Midea Group (00300.HK) up 0.50%, Shenzhen unveils robot high-quality development plan

Fri, 04 Sep 2026 05:31:41 GMT

NewTimeSpace (newtimespace.com) News, on September 4, 2026, the robotics theme weakened amid volatility, while Midea Group (00300.HK) strengthened against the trend. As of 13:26, the company's quote was HK$101.000, up 0.50%.

On the news front, Shenzhen recently issued the "Shenzhen Work Plan for Promoting High-Quality Development of the Intelligent Robotics Industry (2026–2028)." The plan proposes that by 2028, Shenzhen will be built into the world's most influential smart robotics industry highland, creating the country's most vibrant smart robotics innovation enterprise cluster, a globally leading smart robotics software-and-hardware supporting cluster, and an international robot-friendly demonstration city center, as well as a Guangdong-Hong Kong-Macao Greater Bay Area robotics open-source ecosystem center, thereby forming a new industrial pattern featuring the coordinated development of the "two zones and two centers."

Western Securities believes that 2026 is expected to be the first year of scaled mass production for the humanoid robotics industry. At the policy level, embodied intelligence is explicitly promoted as a new economic growth driver; at the technology level, breakthroughs in AI and large models provide the "smart brain"; and at the demand level, the intensifying aging population gives rise to space for labor substitution.

MIDEA GROUP (00300.HK) Comprehensively positions itself within the industrial-grade embodied AI and core automation equipment supply chain through its wholly-owned subsidiary KUKA, one of the "Big Four" global industrial robot giants. The company focuses on the R&D and delivery of high-precision articulated robotic arms, heavy-duty logistics AGVs, and industrial automation software systems. Its intelligent manufacturing solutions are widely deployed across core heavy-asset production lines globally, including automotive manufacturing and electronic semiconductors. Backed by industry-leading delivery metrics for industrial-grade robots, it serves as the foundational infrastructure anchor for the sector.

HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for atopic dermatitis antibody Zhuotuoqibai injection

Fri, 04 Sep 2026 00:02:07 GMT

NewTimeSpace News: On 3 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., has received the acceptance notice issued by the National Medical Products Administration (NMPA) for the marketing application of Zhuotuoqibai injection (SHR-1819 injection) (acceptance number: CXSS2600144), with the proposed indication of treating moderate to severe atopic dermatitis (AD) in adults whose condition is inadequately controlled by or unsuitable for topical therapy.

The filing is mainly based on a multicentre, randomised, double-blind, placebo-controlled Phase III study (study number: SHR-1819-301) in adult patients with moderate to severe AD, led by Professor Xu Jinhua of Huashan Hospital, Fudan University as the principal investigator, with 652 patients with moderate to severe AD enrolled nationwide. The results showed that Zhuotuoqibai injection met both co-primary efficacy endpoints, both significantly superior to the placebo control group, with good safety and tolerability.

SHR-1819 injection is a recombinant humanised monoclonal antibody targeting human IL-4Rα independently developed by the Company, which can simultaneously block the signalling of IL-4 and IL-13, with investigational indications covering a range of type 2 inflammatory diseases including atopic dermatitis, prurigo nodularis and allergic rhinitis. Currently, only two drugs targeting the same target have been approved globally: Dupilumab (brand name: Dupixent), approved in the United States, the European Union, Japan and other countries and regions since 2017 and in China in 2020, and Stapokibart (brand name: Kangyueda), approved in China in 2024. According to the EvaluatePharma database, the combined global sales of Dupilumab and Stapokibart in 2025 were approximately USD 18.076 billion. As of the date of this announcement, the cumulative R&D investment in the SHR-1819 injection project amounts to approximately RMB 385.7 million (unaudited).

HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets

Fri, 04 Sep 2026 00:00:09 GMT

NewTimeSpace News: On 3 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received the acceptance notice issued by the National Medical Products Administration (NMPA) for the marketing application of HRS-7535 tablets (acceptance numbers: CXHS2600122 and CXHS2600124). The proposed indication is for long-term weight management in adults with an initial body mass index (BMI) meeting the following requirements, on the basis of diet control and increased exercise: (i) BMI ≥28kg/m² (obesity), or (ii) BMI ≥24kg/m² (overweight) accompanied by at least one weight-related comorbidity (such as hyperglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and fatty liver).

The filing is based on a multicentre, randomised, double-blind, placebo-controlled, parallel-design pivotal Phase III clinical trial (study number: HRS-7535-303) in adults who are overweight or obese, evaluating the efficacy, safety and tolerability of HRS-7535 tablets at 120mg and 180mg versus placebo in non-diabetic participants with obesity or overweight accompanied by at least one weight-related comorbidity. The study was led by Professor Mu Yiming of the First Medical Centre of the Chinese PLA General Hospital as the principal investigator, with 50 centres initiated nationwide and 556 subjects randomised. The results showed that all dose groups of HRS-7535 tablets achieved all primary and key secondary endpoints at 44 weeks of treatment, with an average weight reduction of up to 10.9% in the 180mg group; the weight-loss effect persisted with continued treatment, with an average weight reduction of up to 11.1% in the 180mg group at week 50; improvements in multiple cardiometabolic indicators were also observed, with safety and tolerability data consistent with other reported oral GLP-1 therapies and no new safety signals identified.

HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, which can promote pancreatic insulin secretion, reduce glucagon secretion and inhibit gastric emptying by activating the human GLP-1R, and can also enhance satiety and suppress appetite by affecting the central nervous system, for the treatment of type 2 diabetes mellitus (T2DM) and weight loss. Globally, the only oral small-molecule GLP-1R agonist approved to date is Lilly's FOUNDAYO (orforglipron), which received FDA approval in April 2026. As of the date of this announcement, the cumulative R&D investment in the HRS-7535 tablets project amounts to approximately RMB 494.4 million (unaudited).

SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China

Thu, 03 Sep 2026 23:44:04 GMT

NewTimeSpace News: On 3 September 2026, Simcere Pharmaceutical Group Limited (stock code: 02096) announced that Kulaiweibai injection (brand name: Yimule), a domestic Class 1 innovative biologic developed under strategic cooperation between the Group and Ruiyang (Shandong) Biopharmaceutical Co., Ltd., has been approved by the National Medical Products Administration (NMPA) for marketing in China, for use in neonates and infants with gestational age of no less than 35 weeks who are about to enter or are born during their first respiratory syncytial virus (RSV) season, for the prevention of lower respiratory tract infection caused by RSV (excluding children with chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), or clinically significant congenital respiratory tract abnormalities). The Group entered into a strategic cooperation with Ruiyang on 20 August 2026, obtaining exclusive commercialisation rights for Yimule in Greater China.

Kulaiweibai is a recombinant humanised IgG1κ monoclonal antibody that provides passive immunity mainly by targeting epitope II of the RSV F protein, with Fc engineering to extend the antibody half-life, offering sustained protection covering the entire RSV season to neonates and infants through a single intramuscular injection. Data from the pivotal Phase III study supporting this approval showed that, at 150 days after administration, Kulaiweibai demonstrated 85.32% protective efficacy against RSV-associated lower respiratory tract infection requiring medical intervention (outpatient, emergency or hospitalisation) and 83.27% protective efficacy against RSV-associated hospitalisation compared with placebo; at 240 days after administration, the two efficacy figures were 82.04% and 78.44% respectively. In addition, a Phase IIIb study in toddlers aged 1 to 2 years is ongoing to further expand the applicable age range.

Ruiyang (Shandong) Biopharmaceutical Co., Ltd. is principally engaged in the R&D and industrialisation of antibody-based biological macromolecular drugs, focusing on passive immunisation prevention and treatment in the infectious disease field, while also laying out innovative directions such as tumour immunology. Simcere Pharmaceutical is an innovation- and R&D-driven pharmaceutical company focusing on neuroscience, oncology, autoimmune diseases and anti-infection.

CMS (00867.HK): Opzelura-Counterpart Baicor (Ruxolitinib Cream) Approved for Atopic Dermatitis in China

Thu, 03 Sep 2026 10:39:43 GMT

NewTimeSpace News: On 3 September 2026, China Medical System Holdings Limited (stock code: 00867) announced that its skin-health focused subsidiary Deme Medical obtained approval from the National Medical Products Administration (NMPA) on 2 September 2026 for the new drug application of ruxolitinib phosphate cream Baicor for mild-to-moderate atopic dermatitis (AD), and received the drug registration certificate on 3 September 2026. The product is indicated for short-term and non-continuous chronic topical treatment of mild-to-moderate AD in non-immunocompromised children aged 2 years and above and adults where other topical treatments are poorly controlled or not recommended, and was granted priority review as a paediatric-friendly new drug.

According to the announcement, Baicor became the first topical JAK inhibitor approved in China for vitiligo in January 2026, and this approval marks its expansion into a second indication.

Hong Kong AI Concept Stock Daily：Most AI chip and large-model names under pressure; Iluvatar CoreX (09903.HK) rose 9.23% against the trend-20260903

Thu, 03 Sep 2026 10:02:33 GMT

I. Market Overview

On September 3, 2026, the three major Hong Kong indices opened higher but closed lower: the Hang Seng Index fell 0.39%, the Hang Seng TECH Index fell 1.08%, and the Hang Seng China Enterprises Index fell 0.77%. The Hang Seng Index's full-day turnover was HK$199.4 billion, and southbound funds recorded a net inflow of HK$3.395 billion. AI concept stocks showed a divergent performance on the day, with the intelligent-driving direction broadly strengthening, while the AI chip and large-model directions were mostly under pressure.

The large-model direction mostly weakened, with MINIMAX-W (00100.HK) rising 3.62% against the trend, KUAISHOU-W (01024.HK) falling 2.62%, and Z.AI, Baidu Group-W, TENCENT, ALIBABA-W, and MEITUAN-W following the declines.

In the AI chip direction, Iluvatar CoreX (09903.HK) rose 9.23%, with HUA HONG GRACE following the gains. BIREN TECH (06082.HK) fell 2.82%, with SMIC, MONTAGE TECHNOLOGY, and GIGADEVICE following the declines.

In the intelligent-driving direction, PONY-W (02026.HK) rose 5.11%, WERIDE-W (00800.HK) rose 2.88%, and HORIZONROBOT-W and ROBOSENSE followed the gains. BLACK SESAME (02533.HK) fell 3.40%.

In the embodied intelligence direction, UBTECH ROBOTICS (09880.HK) edged down 0.06%, and XIAOMI-W (01810.HK) fell 2.21%.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
09903.HK	ILUVATAR COREX	402.200	9.23	AI Chips
02026.HK	PONY-W	55.500	5.11	Autonomous Driving
00100.HK	MINIMAX-W	355.000	3.62	LLM
00800.HK	WERIDE-W	15.360	2.88	Autonomous Driving
01347.HK	HUA HONG GRACE	119.800	1.96	AI Chips
09660.HK	HORIZONROBOT-W	4.370	1.51	Autonomous Driving
02498.HK	ROBOSENSE	17.590	1.44	Autonomous Driving
09880.HK	UBTECH ROBOTICS	79.100	-0.06	Embodied AI
00981.HK	SMIC	68.050	-0.29	AI Chips
02513.HK	Z.AI	1,108.000	-0.81	LLM
09888.HK	BIDU-SW	91.500	-0.92	LLM
03986.HK	GIGADEVICE	466.800	-1.14	AI Chips
00700.HK	TENCENT	433.000	-1.19	LLM
06809.HK	MONTAGETECH	258.400	-1.30	AI Chips
03690.HK	MEITUAN-W	77.650	-1.40	LLM
09988.HK	BABA-SW	107.500	-2.18	LLM
01810.HK	XIAOMI-W	27.440	-2.21	Embodied AI
01024.HK	KUAISHOU-W	32.760	-2.62	LLM
06082.HK	BIRENTECH	42.080	-2.82	AI Chips
02533.HK	BLACK SESAME	10.240	-3.40	Autonomous Driving

Data Source: HKEX. For reference only, not investment advice. Data as of market close on September 3, 2026.

III. AI Industry & Corporate Developments

1. Kimi API now natively supports Codex and Claude Code

On September 2, Moonshot AI announced that, to meet users' need to connect Kimi API within Codex and Claude Code, Kimi API now supports OpenAI's Responses API format and also supports Anthropic's Messages API format. Users of Codex or Claude Code can directly connect to models such as kimi-k3, kimi-k2.7-code-highspeed, kimi-k2.7-code, and kimi-k2.6 via a custom model provider, without converting formats or using a local proxy.

2. Anthropic to release a new version of its AI model Fable

On September 2, it was reported that Anthropic will release a new version of its AI model Fable. The company said Fable 5.1 performs better on programming and scientific-research tasks while also costing less. Anthropic stated that Fable 5.1's per-token price for enterprise users will remain consistent with Fable 5, but it will lower the charge when the model re-invokes previously processed information. The company said the price for this step will be cut by 75%, thereby "significantly reducing" the model's overall operating cost.

3. Google launches two new Gemini models, strengthening programming and cybersecurity capabilities

On September 2, Google officially launched two AI models, Gemini 3.8 Flash and Gemini 3.8 Flash Cyber. Gemini 3.8 Flash focuses on optimizing software engineering, AI agents, and multi-step complex reasoning, with pricing maintained at the previous generation's level—delivering performance upgrades without a price increase. Gemini 3.8 Flash Cyber is a cybersecurity-specific model that can automatically discover vulnerabilities and generate remediation patches, and is made available through the Fairwind program to government agencies, critical infrastructure operators, and software maintenance organizations.

4. Tencent WorkBuddy announces platform launch, to fully open Agent foundation capabilities

On September 2, Tencent WorkBuddy announced that its open platform (open.WorkBuddy.cn) has officially launched, with over 100 ecosystem partners introduced in the first batch, opening up underlying Agent capabilities to smart hardware, industry applications, developers, and others. To date, brands including Plaud, Rokid, Insta360, iFLYTEK, Anker, Hollyland, and JD Jingzao have launched co-branded smart hardware, covering more than 20 fields such as finance, law, healthcare, education, and public welfare.

5. NVIDIA close to acquiring AI company Hugging Face for US$14 billion

On September 2, it was reported that NVIDIA is in advanced talks to acquire AI startup Hugging Face, in a deal that could be worth about US$14 billion. The report said NVIDIA's retention package for acquiring Hugging Face is valued at US$12.9 billion.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
MINIMAX-W	00100.HK	A top-tier player dedicated to omni-modal Artificial General Intelligence (AGI)	The company continuously iterates its video generation model matrix and has partnered with mainstream domestic and overseas chip manufacturers and inference platforms to complete underlying adaptations. The total monthly active users (MAU) of its B2C and B2B LLM applications, along with multimodal API call volumes, maintain rapid growth, further broadening its computing power ecological layout.
PONY-W	02026.HK	Global commercialization leader in L4 autonomous mobility and logistics	The first autonomous driving company in China to secure fully driverless Robotaxi commercial operation permits across all four top-tier cities (Beijing, Shanghai, Guangzhou, Shenzhen). Core operations span autonomous ride-hailing (Robotaxi) and freight services (Robotruck), with Robotaxi deployments across 9 countries and public operations in overseas markets including Croatia, Qatar, Singapore, and South Korea. Targeting a global fleet exceeding 3,000 vehicles across 20+ cities by 2026, the company has achieved positive unit economics per vehicle.
ILUVATAR COREX	09903.HK	Domestic general-purpose GPU pioneer & builder of full-scenario AI compute bases	Established in 2015, it is among the earliest domestic vendors to achieve mass production of general-purpose GPUs. Product lines cover training, inference, and edge computing across the Tiangai, Zhikai, and Tongyang series. In July 2026, it launched its next-gen flagship Tiangai 300 at WAIC, matching the Nvidia Hopper architecture. As of late 2025, it served 340+ clients across 30+ industries, generating core GPGPU revenue of ~RMB 923 million (+149.6% YoY).
HORIZONROBOT-W	09660.HK	China's leading intelligent driving computing solution provider and full‑stack vehicle intelligence enabler	Founded in 2015, it offers ADAS and high‑level autonomous driving solutions. Core products include the Journey-series in-car AI chips (cumulative shipments exceeding 10 million units), the HSD full‑scenario urban driving solution, and the "Starry 6P" cockpit‑driving integrated vehicle intelligence chip. In 2025, it held a 47.7% market share in domestic ADAS for independent brands, with full‑year revenue of RMB 3.758 billion, up 57.7% YoY.
HUA HONG GRACE	01347.HK	Global leader in specialty process wafer foundry	A world‑leading specialty process wafer foundry, the company operates 8‑inch and 12‑inch production lines serving new energy vehicles, industrial control, and data center power management. It provides customized manufacturing in power devices, embedded non‑volatile memory, analog ICs, and power management chips, with multiple automotive‑grade certifications and sustained high capacity utilization.

Autonomous Driving Concept Stocks Watch | BIDU-W (09888.HK) Edges Lower in Afternoon Session; MIIT Outlines Four Key Priorities for ICV & New‑Energy Vehicles in the 15th Five‑Year Plan

Thu, 03 Sep 2026 07:45:20 GMT

NewTimeSpace News: On September 3, 2026,BIDU-W(09888.HK) drifted lower in the afternoon. As of 15:27, the stock traded at HK$91.50, down 0.92%.

On the news front, Baidu’s voluntary conversion from secondary listing to dual‑primary listing on the Hong Kong Stock Exchange took effect on September 1. Baidu is now dual‑primary‑listed on both the Hong Kong Stock Exchange and Nasdaq Global Select Market.

According to Shanghai Securities, the Ministry of Industry and Information Technology (MIIT) has defined four deployment priorities for new‑energy vehicles under the 15th Five‑Year Plan. As reported by Autohome News, on August 26, the State Council Information Office held a press conference in the series“Kick‑off of the 15th Five‑Year Plan”. Xin Guobin, Vice‑Minister of MIIT, stated that the 15th Five‑Year Plan for the Development of Intelligent Connected New‑Energy Vehicle Industry has been formulated, covering product supply quality and supporting‑service provisions.

BIDU-W (09888.HK) Focuses on the R&D of L4 autonomous driving algorithms and the commercialization of unmanned Robotaxis. Leveraged by the ERNIE foundational model and optimized by the Qianfan compute base, its "Apollo Go" autonomous ride-hailing service has achieved large-scale, normalized commercial operations across multiple core cities in China, with cumulative autonomous test mileage exceeding hundreds of millions of kilometers. Through high-frequency, high-confidence real-world road test data cleansing, the company continues to solidify the most robust data asset and algorithmic moat within the HKEX autonomous driving sector.

AI Chip Concept Stocks Watch | ASMPT (00522.HK) Up 2.67%; Broadcom Predicts AI Chip Sales to Surge Sharply

Thu, 03 Sep 2026 05:50:49 GMT

NewTimeSpace (newtimespace.com) News, on September 3, 2026, the chip theme weakened amid volatility while ASMPT (00522.HK) strengthened against the trend. As of 13:46, the stock was quoted at HKD 161.600, up 2.67%.

On the news front, on September 2, Broadcom predicted that its AI chip sales will surge sharply over the next two years. Chief Executive Officer Hock Tan stated that AI chip revenue will double to approximately USD 115 billion in fiscal year 2027 and soar to USD 230 billion in the next fiscal year.

Sinolink Securities pointed out that in the first half of 2026, the electronics industry's revenue and net profit grew 30.98% and 99.38% year-on-year respectively, with the PCB, semiconductor equipment, and design segments performing particularly prominently. Demand for AI servers and high-speed switches has driven both volume and price higher across the supply chain, while domestic substitution has accelerated; orders in the equipment and core components segments have maintained high growth, and profitability has improved markedly.

ASMPT(00522.HK)Engages in R&D and global sales of semiconductor assembly and packaging equipment, advanced packaging equipment, and surface mount technology. Its 2.5D/3D advanced packaging tools, such as thermo-compression bonding (TCB) machines, have been delivered to multiple leading OSATs, IDMs, and memory manufacturers worldwide for volume production of HBM and chiplet-based chips. The company has publicly disclosed multiple follow-on orders from AI-compute related customers.

Humanoid Robot Concept Stock Watch | XIAOMI-W (01810.HK) Weakens Amid Volatility; Musk Predicts 1 Billion Humanoid Robots Globally Within a Decade

Thu, 03 Sep 2026 05:42:56 GMT

NewTimeSpace (newtimespace.com) News, on September 3, 2026, the robot theme rose amid volatility while XIAOMI-W (01810.HK) weakened. As of 13:33, the stock was quoted at HKD 27.320, down 2.64%.

On the news front, Elon Musk said at the G20 Summit that robotics technology will bring leapfrog growth in productivity. He predicted that within the next decade, the global number of humanoid robots will reach 1 billion units. The output of these robots will be at least five times that of humans. He believes the widespread application of humanoid robots could expand the global economic scale more than tenfold.

Kaiyuan Securities stated that the humanoid robot industry is moving from the technology-exploration stage to a critical period of scaled commercial validation and industrial ecosystem build-out. At the policy level, the "15th Five-Year Plan" explicitly identifies intelligent robots as an important direction of new quality productive forces, driving their empowerment of the digital-intelligent transformation of traditional manufacturing. In the first half of 2026, some companies' robot projects have shifted from sample delivery to mass production, with revenue from DC motors and components surging 202.29% year-on-year, indicating accelerated release of demand for core components. As projects in the industrial equipment field continue to increase, micro special motors for robots are expected to become a key development area for future technology and market, with broad application space.

XIAOMI-W(01810.HK) Leverages its massive AIoT ecosystem network and full-stack proprietary AI algorithms to advance the collaborative deployment of consumer- and industrial-grade embodied AI devices. Algorithms for its CyberOne humanoid robot and CyberDog bionic quadruped robot undergo continuous iteration. The underlying multi-modal machine vision, force-control algorithms, and automated scheduling logic are deeply integrated into the "dark factory" operations and flexible manufacturing workflows of Xiaomi's smart factories, establishing a complete closed-loop model of "algorithm + hardware + proprietary manufacturing application scenarios."

CH BIOTECH SER (08037.HK): Penbo (Hainan) BNCT hospital enters into cross-border oncology cooperation agreement with Hong Kong Oncare

Wed, 02 Sep 2026 23:57:13 GMT

NewTimeSpace News: On 2 September 2026, China Biotech Services Holdings Limited (stock code: 08037) announced that Pengbo (Hainan) Boron Neutron Capture Therapy Hospital (the "Hospital"), the Group's flagship boron neutron capture therapy (BNCT) project, has entered into a framework cooperation agreement with Oncare Cancer Centre ("Oncare"), a member of the Tianma Medical Group, a Hong Kong comprehensive oncology specialist institution, to establish cross-border oncology cooperation under an "overseas assessment, domestic treatment, overseas follow-up" model, covering BNCT clinical services, two-way referral, joint multi-disciplinary team (MDT) consultations and post-treatment follow-up.

Under the cooperation agreement, patients meeting the indications may be referred in both directions: Oncare is responsible for compliant overseas education and notification, patient initial screening and assessment, cross-border referral coordination, entry and treatment guidance, and post-treatment overseas rehabilitation and follow-up management, while the Hospital is responsible for BNCT clinical treatment during hospitalisation, inpatient management, medical quality and safety, and timely updates of treatment progress to Oncare; the parties will also conduct joint MDT consultations for screened patients. The framework agreement has a term of one year from signing and may be renewed upon negotiation, with specific implementation arrangements to be set out in separate implementation agreements. Oncare is a Hong Kong comprehensive oncology specialist institution providing full-spectrum cancer care services including radiotherapy, targeted therapy, immunotherapy and in-clinic chemotherapy, and is a member of Tianma Medical Group, whose network covers Singapore, Mainland China, Hong Kong, Malaysia, the Philippines and Vietnam.

The Hospital is the Group's flagship project in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China, which entered trial operation in February 2026, began treating patients in March 2026 and has completed dozens of treatments to date, with approved indications mainly covering head and neck tumours and plans to expand to other solid tumours; according to the announcement dated 3 August 2026, based on three-month post-treatment follow-up, the overall response rate of the first 10 head and neck cancer patients treated with BNCT at the Hospital reached 80%. The Company stated that this cooperation will expand the overseas patient sources for the Hospital's BNCT services by leveraging the pioneering medical policies of the Boao Lecheng pilot zone and Oncare's screening, referral and follow-up capabilities, establishing a closed-loop cross-border service and enabling the Group to expand from the Chinese market to the Asian market.

AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit

Wed, 02 Sep 2026 23:44:07 GMT

NewTimeSpace News: On 3 September 2026, Akeso, Inc. (stock code: 09926) announced that in the randomised, double-blind, controlled, multi-centre Phase III clinical study (AK112-303/HARMONi-2) evaluating the Company's self-developed, globally first-in-class bispecific antibody ivonescimab (PD-1/VEGF) monotherapy versus pembrolizumab monotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS≥1%), the pre-specified interim analysis of overall survival (OS) assessed by the Independent Data Monitoring Committee (IDMC) met the key secondary OS endpoint, achieving positive results with statistical significance and clinical benefit. Detailed data from the results will be presented at future international academic conferences and published in academic journals.

The study enrolled 398 subjects in total, with progression-free survival (PFS) as the primary endpoint and OS as the key secondary endpoint. In May 2024, the study met its primary PFS endpoint, with median PFS of 11.14 months and 5.82 months in the ivonescimab and control groups respectively, and a PFS HR of 0.51 (P<0.0001). The indication was approved for marketing in China in 2025; ivonescimab has overcome the contraindication of VEGF agents in patients with squamous carcinoma, offering patients a superior "chemo-free" option.

Ivonescimab (PD-1/VEGF) is the world's first-in-class PD-1/VEGF bispecific tumour immunotherapy drug, approved by the NMPA on 24 May 2024 for the treatment of EGFR-mutated non-squamous NSCLC progressing after EGFR-TKI therapy, with a new indication approved on 25 April 2025 for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC (both indications included in the latest National Reimbursement Drug List), and a further new indication approved on 12 August 2026 for first-line treatment of squamous NSCLC. Ivonescimab has initiated 60 Phase II/III clinical studies across more than 40 indications, including lung cancer, biliary tract cancer, head and neck squamous cell carcinoma and triple-negative breast cancer, of which 17 registrational Phase II/III clinical studies are being efficiently advanced.

CUTIA-B (02487.HK): BLA for CU-20101 botulinum toxin type A for injection accepted by NMPA

Wed, 02 Sep 2026 23:39:30 GMT

NewTimeSpace News: On 3 September 2026, Cutia Therapeutics (stock code: 02487) announced that the biologics licence application (BLA) for CU-20101 (botulinum toxin type A for injection) developed by the Group has been accepted by the National Medical Products Administration (NMPA), for the indication of improving moderate to severe glabellar lines.

According to the announcement, CU-20101 will not use animal-derived materials or human serum albumin in its manufacturing process, thereby eliminating the risks of transmissible spongiform encephalopathy (TSE) infection and related allergic reactions, and is expected to have a favourable safety profile. CU-20101 will further enrich the Group's dermatology product matrix and facilitate synergies with the Group's existing products; given the broad demand in the skin treatment market, a diversified product portfolio is expected to help the Group capture a larger market share.

The Company noted that it cannot ensure that CU-20101 will ultimately be successfully developed and sold.

Hong Kong AI Concept Stock Daily：Large Models Mixed, AI Chip Sector and Intelligent Driving Direction Under Collective Pressure-20260902

Wed, 02 Sep 2026 09:49:40 GMT

I. Market Overview

On September 2, 2026, the three major Hong Kong indices trended lower amid volatility. The Hang Seng Index edged down 0.07%, the Hang Seng TECH Index fell 0.74%, and the Hang Seng China Enterprises Index edged down 0.15%. Full-day turnover of the Hang Seng Index reached HKD 216.7 billion, with southbound funds recording a net inflow of HKD 4.093 billion. AI concept stocks diverged in performance on the day — large models were mixed, while the AI chip sector and the intelligent driving direction came under collective pressure.

Large Model direction: MEITUAN-W (03690.HK) rose 2.74% against the trend, and MINIMAX-W (00100.HK) gained 1.72%. Z.AI (02513.HK) fell 5.26%, with ALIBABA-W, TENCENT, BIDU-SW, and KUAISHOU-W following lower.

AI Chip direction: BIREN TECH (06082.HK) fell 5.71%, ILUVATAR COREX dropped 3.11%, and HUA HONG GRACE, SMIC, GIGADEVICE, and Montage Technology followed lower.

Intelligent Driving direction: PONY-W (02026.HK) fell 6.47%, HORIZONROBOT-W (09660.HK) tumbled 6.31%, and BLACK SESAME, ROBOSENSE, and WERIDE-W followed lower.

Embodied Intelligence direction: UBTECH ROBOTICS (09880.HK) fell 2.88%, while XIAOMI-W (01810.HK) rose 1.81% against the trend.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
03690.HK	MEITUAN-W	78.750	2.74	LLM
01810.HK	XIAOMI-W	28.060	1.81	Embodied AI
00100.HK	MINIMAX-W	342.600	1.72	LLM
09988.HK	BABA-SW	109.900	-0.45	LLM
03986.HK	GIGADEVICE	472.200	-0.67	AI Chips
06809.HK	MONTAGETECH	261.800	-0.68	AI Chips
00700.HK	TENCENT	438.200	-0.72	LLM
00981.HK	SMIC	68.250	-0.87	AI Chips
09888.HK	BIDU-SW	92.350	-1.44	LLM
00800.HK	WERIDE-W	14.930	-2.42	Autonomous Driving
01347.HK	HUA HONG GRACE	117.500	-2.81	AI Chips
09880.HK	UBTECH ROBOTICS	79.150	-2.88	Embodied AI
01024.HK	KUAISHOU-W	33.640	-2.89	LLM
09903.HK	ILUVATAR COREX	368.200	-3.11	AI Chips
02498.HK	ROBOSENSE	17.340	-3.67	Autonomous Driving
02513.HK	Z.AI	1,117.000	-5.26	LLM
02533.HK	BLACK SESAME	10.600	-5.61	Autonomous Driving
06082.HK	BIRENTECH	43.300	-5.71	AI Chips
09660.HK	HORIZONROBOT-W	4.305	-6.31	Autonomous Driving
02026.HK	PONY-W	52.800	-6.47	Autonomous Driving

Data Source: HKEX. For reference only, not investment advice. Data as of market close on September 2, 2026.

III. AI Industry & Corporate Developments

1. Google to Release Gemini 3.8 Flash AI Model This Wednesday

On September 1, it was reported that Google-C (GOOG.US) will release the Gemini 3.8 Flash AI model this Wednesday. In internal programming-tool testing, Google employees preferred using Gemini 3.8 Flash over Claude Opus. Google has stepped up its investment in the field of reinforcement learning.

2. Samsung Unveils Next-Generation Memory Strategy: HBM5 Performance Target Raised to Twice HBM4E

On September 1, it was reported that Samsung Electronics (005930.KR) plans to raise the performance of its next-generation high-bandwidth memory (HBM) HBM5 to twice that of HBM4E, while the subsequent-generation product zHBM targets a performance level reaching 8 times that of HBM4E. Samsung will center its efforts on 3D structural innovation to compete for dominance in the next-generation memory market.

3. Lei Jun: Xiaomi Pengcheng to Officially Launch on September 7

On September 2, it was reported that Lei Jun, founder, Chairman and CEO of Xiaomi, stated on Weibo that Xiaomi's autumn flagship new-product launch event is set for 7:00 PM on September 7, with the Xiaomi Pengcheng N70 Pro / N70 Max / N90 Max officially launching. Also unveiled at the same event are two additional flagship products: the all-new foldable flagship phone Xiaomi 18 Fold and the Xiaomi Pad 9 Pro Max, debuting the Xuanjie O3 AI flagship processor.

4. Tencent Hunyuan Launches Hy4 preview Lightweight Model

On September 1, it was reported that the Tencent Hunyuan team announced the launch of the Hy4 preview lightweight model, compressing Hy4 preview's weights from 1.5TB to approximately 214GB. According to the introduction, the compressed model's long-text comprehension is nearly on par with the original model; multi-turn long-context retrieval is essentially at the same level as the original, with only a slight decline in mathematics — all within an acceptable range overall. It covers daily coding assistance, tool calling, long-document processing, and general Q&A.

5. Alibaba Cloud Announces Price Cut for Qwen3-VL-Rerank Model

On September 1, it was reported that Alibaba Cloud announced that the large-model service platform Bailian will, starting from 10:13:53 on August 31, 2026 (Beijing time), lower the billing unit price for the Qwen3-VL-Rerank model in the Beijing region: text input will be reduced from RMB 0.7 per million tokens to RMB 0.5 per million tokens, and multimodal input from RMB 1.8 per million tokens to RMB 0.5 per million tokens.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
MINIMAX-W	00100.HK	A top-tier player dedicated to omni-modal Artificial General Intelligence (AGI)	The company continuously iterates its video generation model matrix and has partnered with mainstream domestic and overseas chip manufacturers and inference platforms to complete underlying adaptations. The total monthly active users (MAU) of its B2C and B2B LLM applications, along with multimodal API call volumes, maintain rapid growth, further broadening its computing power ecological layout.
XIAOMI-W	01810.HK	Full-stack AI technology giant anchored by the "Human x Car x Home" ecosystem	Its foundational model family MiMo has entered the top tier of global open-source models; MiMo-V2-Pro features over 1 trillion parameters, while MiMo-V2.5-Pro tied for 1st globally among open-source models with a score of 54 on the Artificial Analysis composite index. AI capabilities fully power the "Human x Car x Home" ecosystem, driving iterative upgrades in the CyberOne humanoid and CyberDog bionic quadrupeds. Multimodal computer vision, force-control algorithms, and automated dispatch logics are deeply integrated into dark-factory production and flexible manufacturing.
ILUVATAR COREX	09903.HK	Domestic general-purpose GPU pioneer & builder of full-scenario AI compute bases	Established in 2015, it is among the earliest domestic vendors to achieve mass production of general-purpose GPUs. Product lines cover training, inference, and edge computing across the Tiangai, Zhikai, and Tongyang series. In July 2026, it launched its next-gen flagship Tiangai 300 at WAIC, matching the Nvidia Hopper architecture. As of late 2025, it served 340+ clients across 30+ industries, generating core GPGPU revenue of ~RMB 923 million (+149.6% YoY).
HORIZONROBOT-W	09660.HK	China's leading intelligent driving computing solution provider and full‑stack vehicle intelligence enabler	Founded in 2015, it offers ADAS and high‑level autonomous driving solutions. Core products include the Journey-series in-car AI chips (cumulative shipments exceeding 10 million units), the HSD full‑scenario urban driving solution, and the "Starry 6P" cockpit‑driving integrated vehicle intelligence chip. In 2025, it held a 47.7% market share in domestic ADAS for independent brands, with full‑year revenue of RMB 3.758 billion, up 57.7% YoY.
MEITUAN-W	03690.HK	AI technology pioneer in local life services	Its AI-native community application “Miyu” has demonstrated operational value in physical retail and dining environments, boosting merchant efficiency. The company continuously enhances search, recommendation, and dispatch algorithms across its local commerce ecosystem using proprietary foundation models. By deploying AI Agent technologies in customer service, merchant marketing assistants, and instant delivery route planning, the company improves dual-sided operational efficiency and management precision.

PEGBIO CO-B (02565.HK): Enters Joint R&D Collaboration with SN BioScience for Long-Acting Metabolic Disease Peptides

Wed, 02 Sep 2026 09:03:15 GMT

NewTimeSpace News: On 2 September 2026, PegBio Co., Ltd. (stock code: 02565) announced that it has entered into a material transfer agreement with SN BioScience, Inc., a Korean biotech company, under which SN BioScience will apply its self-developed serinol nucleic acid (SNA) long-acting drug delivery platform to three of the Group's self-developed innovative metabolic disease peptide candidates, including APGP6, with joint research to be conducted on formulation and long-acting delivery of the candidates.

According to the announcement, the collaboration covers three drug candidates at once rather than a single product, allowing parallel validation of the technical fit between the SNA platform and the Group's next-generation peptide assets, and exploring the potential to extend duration of action, optimise dosing regimens and improve overall product profiles.

HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA

Wed, 02 Sep 2026 08:37:16 GMT

NewTimeSpace News: On 2 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692) announced that the marketing authorisation application for HS-20093 for injection, an innovative drug of the Group, has been accepted by the National Medical Products Administration (NMPA) for the treatment of adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based therapy.

According to the announcement, HS-20093 is a B7-H3-targeted antibody-drug conjugate (ADC) independently developed by the Group.

Autonomous Driving Concept Stocks Watch | RoboSense (02498.HK) Weakens in Afternoon Session, Peacock‑chip‑powered LiDAR E2 Enters Mass‑production Delivery

Wed, 02 Sep 2026 07:30:19 GMT

NewTimeSpace News: On September 2, 2026, RoboSense (02498.HK) traded lower in the afternoon. As of 15:05, the stock stood at HK$17.39, down 3.39%.

According to RoboSense’s financial report, the company unveiled its Genesis SPAD‑SoC architecture together with the Phoenix and Peacock chip families in April 2026. In the third quarter of this year, the second‑generation all‑solid‑state LiDAR E2 equipped with Peacock chip has started mass‑production delivery. Under current project schedules, deliveries of Peacock‑chip‑integrated products are expected to exceed 200,000 units in the second half of 2026.

As reported by Securities Times, on September 1, the Ministry of Commerce, the Ministry of Industry and Information Technology and the State Administration for Market Regulation jointly issued the *Guidelines on Overseas Competitive Practices and Compliance Development for the Automotive Industry* (hereinafter referred to as the Guidelines). It puts forward general reference guidance covering overseas marketing and other competitive activities of automotive enterprises, as well as compliance building for overseas work safety, quality management, labor protection and data security.

RoboSense(02498.HK) Focuses on the scaled mass production and delivery of LiDAR and core perception solutions for the autonomous driving perception layer. As a leading tier-1 supplier in the intelligent driving hardware supply chain, it has secured massive design wins across a wide range of models from global mainstream automakers and new energy vehicle (NEV) startups. The company maintains industry-leading growth in single-quarter automotive LiDAR shipments. Through process optimization and economies of scale, it continuously drives down per-unit hardware costs, solidifying its market share in the core perception infrastructure for autonomous driving.

AI Chip Concept Stocks Watch | SMIC (00981.HK) opens lower and trades sideways; Samsung plans to double next-gen HBM performance

Wed, 02 Sep 2026 05:41:17 GMT

NewTimeSpace (newtimespace.com) News, on September 2, 2026, the chip theme continued to weaken, with SMIC (00981.HK) opening lower and trading sideways. As of 13:32, the company was quoted at HKD 68.150, down 1.02%.

On the news front, Samsung Electronics (005930.KR) plans to boost the performance of its next-generation high-bandwidth memory (HBM), HBM5, to twice that of HBM4E, while the performance target of the subsequent-generation product zHBM is set at 8 times that of HBM4E. Samsung will center on 3D structural innovation to compete for dominance in the next-generation memory market.

Guotai Haitong Securities noted that semiconductor equipment investment is jointly driven by advanced logic, HBM / advanced DRAM, advanced packaging, and domestic substitution; the sharp increase in capital expenditures by overseas majors signals that the semiconductor industry is entering a new round of major demand cycle, and AI is driving HBM demand and lifting the prosperity of overall DRAM demand.

SMIC (00981.HK)Provides IC wafer foundry and related technical services. It is the largest pure-play wafer foundry in China by capacity and offers the broadest coverage of process nodes. Its mature and select advanced process lines address applications including smart terminals, IoT, and computing chips. Based on its periodic disclosures, wafer shipments, capacity utilization, and revenue are at historically high levels.

Humanoid Robot Concept Stock Observation | UBTECH ROBOTICS (09880.HK) fluctuates lower, down 3.50%; H1 2026 humanoid robot sales exceed 900 units

Wed, 02 Sep 2026 05:31:11 GMT

NewTimeSpace (newtimespace.com) News, on September 2, 2026, the robot theme opened lower and traded sideways, with UBTECH ROBOTICS (09880.HK) continuing to weaken. As of 13:20, the company was quoted at HKD 78.650, down 3.50%.

On the news front, the recently disclosed interim report showed that UBTECH ROBOTICS' revenue from full-size embodied-intelligence humanoid robot products and solutions rose to RMB 590 million, surging 1,445.0% year-on-year. The share of this segment's revenue in total revenue jumped directly from 6.1% in the same period last year to 46.5%, replacing other businesses to become the company's largest primary business and core growth engine. In terms of deliveries, full-size embodied-intelligence humanoid robots achieved sales of 921 units in the first half.

CGS noted that embodied intelligence is upgrading toward "one brain, multiple forms / multiple machines," with key technologies such as tactile sensing and electronic skin achieving concentrated breakthroughs and the industry chain becoming increasingly complete; mainstream automakers including Xiaomi and BYD have already carried out deployment verification on actual production lines, covering scenarios such as material handling and loading/unloading operations; domestic humanoid robot batch deployment is accelerating, with first-half shipments accounting for 97% of the global total, and the industry has entered a stage of scaled implementation.

UBTECH ROBOTICS (09880.HK) Focuses on humanoid robot complete machine R&D, full-stack motion control algorithms, and commercial deployment across industrial and logistics scenarios. Its core product, the Walker S series humanoid robot, has deeply integrated into the final assembly lines of multiple leading NEV manufacturers, executing on-site operations such as the flexible handling of automotive components, precision assembly, and intelligent quality inspection. The company pioneers the leap from laboratory prototypes to real-world industrial automation and mass production applications, holding immense technological scarcity and a definitive premium as a pure-play robotics asset.

CSPC PHARMA (01093.HK): ADC candidate SYS6010 receives another Breakthrough Therapy designation in China for recurrent or metastatic head and neck squamous cell carcinoma

Tue, 01 Sep 2026 11:06:48 GMT

NewTimeSpace News: On 1 September 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) announced that SYS6010, developed by the Group, has recently been granted another Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China, with the intended indication of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in patients who have failed prior immunotherapy and platinum-based chemotherapy.

SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), composed of a humanized anti-EGFR monoclonal antibody conjugated via a cleavable linker to a topoisomerase I inhibitor payload. It specifically binds to EGFR on tumor cell surfaces and releases the cytotoxic payload intracellularly after internalization. According to the GLOBOCAN 2024 global cancer statistics report by the International Agency for Research on Cancer of the World Health Organization, head and neck squamous cell carcinoma records approximately 845,000 new cases and 392,000 deaths globally each year, with approximately 87,000 new cases and 48,000 deaths annually in China, and a five-year overall survival rate of only 40% to 50%.

The announcement stated that the product has markedly improved the objective response rate in patients with recurrent or metastatic HNSCC who failed prior immunotherapy and platinum-based chemotherapy, with durable responses, and a pivotal Phase III clinical trial of the product as monotherapy for the indication is underway. The product has previously received two Breakthrough Therapy designations from the NMPA, for EGFR-mutant advanced non-small cell lung cancer (NSCLC) after failure of EGFR-TKI and platinum-based chemotherapy, and for unresectable locally advanced or metastatic esophageal squamous cell carcinoma after failure of first-line platinum-based chemotherapy and immune checkpoint inhibitors.

View announcement.

CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2056 tablets for major depressive disorder officially initiated in China

Tue, 01 Sep 2026 10:57:30 GMT

NewTimeSpace News: On 1 September 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) announced that the Phase I clinical trial (protocol number: SYH2056-001) of SYH2056 tablets, developed for the treatment of major depressive disorder, has been officially initiated in China. The trial evaluates the safety, tolerability, pharmacokinetic profile and food effect of a single oral dose of the product in healthy participants, and participant recruitment and screening are actively underway.

SYH2056 is a small-molecule partial 5-HT2A receptor agonist developed by the Group. While exerting partial agonist activity on the 5-HT2A receptor, the product preserves synaptic plasticity in neurons, and a single dose demonstrated antidepressant efficacy comparable to or better than similar products across multiple animal models. Preclinical studies indicated low risks of off-target effects, hallucinogenic potential and drug dependence.

View announcement.

Hong Kong AI Concept Stock Daily：Tencent Hunyuan Hy4 Preview Call Volume Surges; Most AI Concept Stocks Weaken-20260901

Tue, 01 Sep 2026 09:48:43 GMT

I. Market Overview

On September 1, 2026, the three major Hong Kong stock indexes all closed lower. AI concept stocks showed divergent performance on the day, with most weakening, while the chip theme declined across the board. The Hang Seng Index fell 0.93%, the Hang Seng TECH Index fell 1.49%, and the Hang Seng China Enterprises Index fell 0.59%. Total market turnover was HKD 238.7 billion, with southbound funds recording net inflows of HKD 7.757 billion.

In the large-model space, KUAISHOU-W (01024.HK) received an investment from the National Artificial Intelligence Fund and rose 3.16% against the market, while MINIMAX-W (00100.HK) fell 3.50%; Z.AI, ALIBABA-W, TENCENT, BIDU-SW, and MEITUAN-W followed lower.

AI chips declined across the board, with SMIC (00981.HK) falling 2.69%, while HUA HONG GRACE, ILUVATAR COREX, MONTAGE TECHNOLOGY, GIGADEVICE, and BIREN TECH followed lower.

The intelligent driving space saw divergent moves, with BLACK SESAME (02533.HK) — whose first-half results surged — rising 13.21%, and PONY-W following higher. HORIZONROBOT-W (09660.HK) fell 2.65%, while WERIDE-W and ROBOSENSE followed lower.

In the embodied intelligence space, UBTECH ROBOTICS (09880.HK) fell 3.89%, and XIAOMI-W (01810.HK) dipped slightly by 0.22%.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
02533.HK	BLACK SESAME	11.230	13.21	Autonomous Driving
01024.HK	KUAISHOU-W	34.640	3.16	LLM
02026.HK	PONY-W	56.450	0.98	Autonomous Driving
01810.HK	XIAOMI-W	27.560	-0.22	Embodied AI
02498.HK	ROBOSENSE	18.000	-0.33	Autonomous Driving
00800.HK	WERIDE-W	15.300	-0.46	Autonomous Driving
02513.HK	Z.AI	1,179.000	-1.34	LLM
06082.HK	BIRENTECH	45.920	-1.50	AI Chips
01347.HK	HUA HONG GRACE	120.900	-1.71	AI Chips
06809.HK	MONTAGETECH	263.600	-2.01	AI Chips
09903.HK	ILUVATAR COREX	380.000	-2.11	AI Chips
03986.HK	GIGADEVICE	475.400	-2.22	AI Chips
00700.HK	TENCENT	441.400	-2.56	LLM
09888.HK	BIDU-SW	93.700	-2.60	LLM
09660.HK	HORIZONROBOT-W	4.595	-2.65	Autonomous Driving
00981.HK	SMIC	68.850	-2.69	AI Chips
03690.HK	MEITUAN-W	76.650	-2.85	LLM
09988.HK	BABA-SW	110.400	-3.33	LLM
00100.HK	MINIMAX-W	336.800	-3.50	LLM
09880.HK	UBTECH ROBOTICS	81.500	-3.89	Embodied AI

Data Source: HKEX. For reference only, not investment advice. Data as of market close on September 1, 2026.

III. AI Industry & Corporate Developments

1. Z.AI's First-Half Total Revenue Reaches RMB 954 Million, Up 399.7% Year-on-Year

Z.AI (02513.HK) financial results show that total revenue for the first half of 2026 was RMB 954 million, up 399.7% year-on-year. Its business focus shifted from on-premise deployment to cloud-based MaaS, with the API revenue share rising to 86.5% and gross margin turning positive from negative to 24.6%. Token call volume grew more than 40-fold, while the average API price increased 101%. The company recorded a net loss of RMB 2.072 billion, with R&D investment reaching RMB 2.131 billion.

2. SK Hynix Considers Joint-Venture Plant in Japan to Meet AI Storage Demand

According to news on August 31, South Korea's SK Hynix is studying the feasibility of building a memory chip plant in Japan as a joint venture, to cope with the growth in storage demand driven by the artificial intelligence (AI) boom while keeping production costs under control. SK Group Chairman Chey Tae-won said the company is searching for suitable sites across Japan, with the primary consideration being "ample electricity and water resources," but did not disclose potential partners or specific locations.

3. Tencent Hunyuan Hy4 Preview Call Volume Surges; WorkBuddy Has Carried Out Emergency Capacity Expansion

On August 31, Tencent Hunyuan posted that since Hunyuan Hy4 preview was first integrated and launched on WorkBuddy on August 28, 2026, its markedly improved agent capabilities have drawn active trial and enthusiastic feedback from a wide range of users and developers, and queuing appeared in the WorkBuddy task queue on its very first day online, for which it apologized sincerely. To safeguard the user experience, the company has carried out emergency capacity expansion for the Hy4 preview inference cluster and will continue to allocate resources dynamically. However, constrained by total high-end computing capacity and concentrated peak concurrency, it does not rule out queuing continuing during certain periods.

4. OpenAI Reportedly Purchases Tens of Thousands of Apple Macs for AI Training

According to news on August 31, OpenAI has procured tens of thousands of Apple Mac mini and Mac Studio units, dedicated to reinforcement learning training and the development of computer-operation AI agents. All the Mac mini and Mac Studio units OpenAI purchased come without monitors or keyboards, rather than MacBooks, and it has repeatedly asked Apple to expedite delivery amid strong demand. Apple's M-series chips adopt a unified memory architecture that lets the CPU, GPU, and others share the same memory pool, reducing the performance loss from data transfer during AI training. Unified memory capacity in some high-end chips reaches up to 512GB, and the thermal design of the Mac mini and Mac Studio is also better suited to running training tasks over extended periods.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
KUAISHOU-W	01024.HK	A leading multimodal content generation platform in China	Kling AI has completed independent financing with a total cap of USD 3 billion, at a post-money valuation of USD 18 billion, setting a global record for video foundation model companies, with plans to initiate a Hong Kong IPO within the next 12 months. Kling AI's quarterly revenue has exceeded 650 million RMB, with an Annualized Run Rate (ARR) of nearly USD 500 million. Its general LLM “KwaiYii” and video generation model “Kling” are undergoing continuous iteration, demonstrating high commercial conversion efficiency in scenarios such as e-commerce live streaming and automated marketing.
XIAOMI-W	01810.HK	Full-stack AI technology giant anchored by the "Human x Car x Home" ecosystem	Its foundational model family MiMo has entered the top tier of global open-source models; MiMo-V2-Pro features over 1 trillion parameters, while MiMo-V2.5-Pro tied for 1st globally among open-source models with a score of 54 on the Artificial Analysis composite index. AI capabilities fully power the "Human x Car x Home" ecosystem, driving iterative upgrades in the CyberOne humanoid and CyberDog bionic quadrupeds. Multimodal computer vision, force-control algorithms, and automated dispatch logics are deeply integrated into dark-factory production and flexible manufacturing.
ILUVATAR COREX	09903.HK	Domestic general-purpose GPU pioneer & builder of full-scenario AI compute bases	Established in 2015, it is among the earliest domestic vendors to achieve mass production of general-purpose GPUs. Product lines cover training, inference, and edge computing across the Tiangai, Zhikai, and Tongyang series. In July 2026, it launched its next-gen flagship Tiangai 300 at WAIC, matching the Nvidia Hopper architecture. As of late 2025, it served 340+ clients across 30+ industries, generating core GPGPU revenue of ~RMB 923 million (+149.6% YoY).
PONY-W	02026.HK	Global commercialization leader in L4 autonomous mobility and logistics	The first autonomous driving company in China to secure fully driverless Robotaxi commercial operation permits across all four top-tier cities (Beijing, Shanghai, Guangzhou, Shenzhen). Core operations span autonomous ride-hailing (Robotaxi) and freight services (Robotruck), with Robotaxi deployments across 9 countries and public operations in overseas markets including Croatia, Qatar, Singapore, and South Korea. Targeting a global fleet exceeding 3,000 vehicles across 20+ cities by 2026, the company has achieved positive unit economics per vehicle.
BLACK SESAME	02533.HK	Leading provider of automotive‑grade computing SoCs and SoC‑based solutions for intelligent vehicles	Founded in 2016 and listed on the HKEX in 2024 as the “first smart car AI chip stock”, the company offers the Huashan series (assisted driving) and Wudang series (cross‑domain computing). Huashan A1000 has been integrated into models from Geely, BYD and others; Wudang C1200 advanced to mass production in 2025; Huashan A2000 is the world's first 7nm panoramic high‑compute chip. 2025 revenue reached RMB 822 million, up 73.4% YoY.

Autonomous Driving Concept Stocks Watch | XPENG-W (09868.HK) Trades Lower in Afternoon Session, August New Vehicle Deliveries Hit 39,107 Units, Up 4% Year‑on‑Year

Tue, 01 Sep 2026 07:50:41 GMT

NewTimeSpace News: On September 1, 2026, XPENG-W (09868.HK) edged lower in afternoon trading. As of 15:38 HKT, the stock traded at HK$44.64, down 0.58%.

In news updates, Xpeng released its August 2026 delivery figures. The firm delivered 39,107 new vehicles in the month, representing a 4% year‑on‑year increase and a roughly 2.8% month‑on‑month rise from July’s 38,027 units. By the end of July, Xpeng’s cumulative global vehicle deliveries had surpassed 1.2 million units.

Guosheng Securities commented that the Robotaxi market features long‑term growth potential. It is positive about Xpeng’s business model of joint operations with Amap and overseas mobility platforms. Since launching internal trials in July, Xpeng’s mass‑produced Robotaxi equipped with VLA2.0 has completed more than 2,000 internal test ride‑hailing orders in Guangzhou. The company has recently finished development of its cloud remote takeover platform, targeting to launch passenger‑carrying operations without in‑vehicle safety drivers in 2027.

AI Chip Concept Stocks Watch | HUA HONG GRACE (01347.HK) Falls Nearly 2%; CXMT Begins Small-Batch Production of HBM3E

Tue, 01 Sep 2026 05:42:10 GMT

NewTimeSpace (newtimespace.com) News, on September 1, 2026, the chip theme weakened, and HUA HONG GRACE (01347.HK) fluctuated lower. As of 13:35, the stock was quoted at HKD 120.600, down 1.95%.

On the news front, CXMT has begun small-batch production of HBM3E and plans to expand capacity in 2027, with domestic chip design teams such as CAMBRICON and Alibaba T-Head testing its compatibility with their self-developed processors.

SCS noted that DeepSeek-V4 has achieved Day-0 adaptation across nine types of domestic chips, Huawei's CANN has been fully open-sourced, and Z.AI's GLM-5.3-Flash is the first to provide external services relying on domestic chip clusters in large-scale traffic scenarios, with its per-token cost already comparable to that of mainstream NVIDIA GPUs. Domestic chips are moving from "usable" to "easy to use," with increasingly high cost-effectiveness; as computing-power demand and policy reinforce each other, the localization process has entered a phase of volume delivery.

Humanoid Robot Concept Stocks Watch | MIDEA GROUP (00300.HK) Fluctuated Lower by 0.79%; Goldman Sachs Sharply Raises Humanoid Robot Forecasts

Tue, 01 Sep 2026 05:29:28 GMT

NewTimeSpace (newtimespace.com) News, on September 1, 2026, the robotics theme weakened, and MIDEA GROUP (00300.HK) fluctuated lower. As of 13:22, the stock was quoted at HKD 100.600, down 0.79%.

On the news front, in its interim report, MIDEA GROUP looked ahead to the second half of 2026 and set out its operating approach for the industrial end and for domestic and overseas markets. MIDEA GROUP will hold firm on its core base of white goods and HVAC businesses, steadily expand sub-core businesses such as robotics, new energy, and data center liquid cooling, and drive its ToC and ToB businesses to form a "growth relay."

In its latest report, GOLDMAN SACHS noted that its forecast for global humanoid robot shipments in 2030 has been sharply raised from 256,000 units to 890,000 units, and for 2035 from 1.40 million units to 6.50 million units, with the corresponding market size reaching USD 138 billion. The rationale behind the upgrade is that multiple manufacturers have entered mass-production stages, open-source tools have become more plentiful, financing processes have accelerated, and government policy support is in place.

LAEKNA-B (02105.HK): First subject enrolled in Phase I clinical study of LAE118 for advanced solid tumours

Tue, 01 Sep 2026 01:04:02 GMT

NewTimeSpace News: On 1 September 2026, Laekna, Inc. (stock code: 02105) announced that the Group has initiated subject recruitment for the Phase I clinical study of LAE118 for the treatment of advanced solid tumours in China, with the first subject enrolled. LAE118 is a novel PI3Kα pan-mutation selective inhibitor independently developed by the Group, which has obtained investigational new drug (IND) approval from the US FDA and the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration as of the date of this announcement.

In June 2026, the Group entered into an exclusive licence agreement with Vasque Bio, Inc. Under the agreement, the Group is entitled to receive upfront and milestone payments of up to USD 527 million in aggregate, which are non-refundable and non-creditable, as well as tiered sales royalties of single-digit to double-digit percentages of the future net sales of LAE118 in the licensed territory. The Group is also entitled, without additional consideration, to equity interests of up to high double-digit percentages of the issued ordinary shares of Vasque Bio, or cash payments in lieu of such ordinary shares. If Vasque Bio completes an eligible strategic cooperation or acquisition transaction meeting certain conditions related to the use of LAE118, the Group will be entitled to additional payments of up to 50% of the value of such strategic transaction.

Vasque Bio is a US-based clinical-stage biotechnology company focused on developing innovative therapies for serious rare diseases, supported by a consortium of leading life science investors including The Column Group (TCG) and F-Prime, while the Group focuses on developing LAE118 as an oncology therapy outside the licensed territory. The Company noted that LAE118 may ultimately not be successfully developed and commercialised.

CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2092 for weight management initiated in China

Tue, 01 Sep 2026 00:59:20 GMT

NewTimeSpace News: On 31 August 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) announced that the Phase I clinical trial of SYH2092 injection, developed by the Group for weight management in adults who are overweight or obese, has been formally initiated at the first clinical trial centre in China.

SYH2092 is an amylin receptor agonist. According to the announcement, by optimising agonist activity, the product is expected to improve efficacy while maintaining a manageable tolerability profile, and by optimising fatty acid modification, it can prolong the half-life in vivo with the potential to deliver durable weight-loss benefits. Preclinical studies have shown that, compared with several amylin analogues currently in clinical development, the product demonstrates higher target agonist activity, significant weight-loss effects and sustained weight-maintenance effects.

The Group obtained the drug clinical trial approval notice for the product from the National Medical Products Administration in August 2026 and initiated the Phase I clinical trial after approval. The Phase I trial aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose administration of the product in healthy participants. The product is expected to bring significant clinical benefits to weight management in obese patients and improve glycaemic control in adults with type 2 diabetes mellitus (T2DM), and participant recruitment and screening for the Phase I clinical trial are being actively progressed.

CUMENSION-B (01477.HK): First Patient Dosed in Phase III Clinical Trial of OT-202 for Dry Eye Disease

Mon, 31 Aug 2026 10:47:29 GMT

NewTimeSpace News: On August 31, 2026, Ocumension Therapeutics (stock code: 01477) announced that the first patient has been dosed in the Phase III clinical trial of OT-202 (spleen tyrosine kinase inhibitor/vascular endothelial growth factor receptor 2), an investigational treatment for dry eye disease (DED), conducted in the People's Republic of China.

OT-202 is the Company's self-developed first-in-class drug candidate for moderate-to-severe DED. It acts as a dual-target inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor 2, producing synergistic anti-inflammatory effects. In the Phase I clinical trial completed in February 2023, OT-202 demonstrated favorable safety and tolerability in healthy adult subjects. The Phase II clinical trial completed enrollment of 213 patients in China in November 2023, with results published in Ophthalmology, a leading international ophthalmology journal, and the trial met its primary endpoint in March 2024.

The announcement noted that the successful dosing of the first patient marks an important milestone in OT-202's clinical development in China and reflects the Group's commitment to advancing innovative therapies for DED patients. The Company cautioned that there is no assurance OT-202 will ultimately be successfully commercialized, and advised shareholders and potential investors to exercise caution when dealing in the Company's shares.

The source of this information is the HKEX announcement.

Hong Kong AI Concept Stock Daily：H1 Revenue Surges Nearly 2,000%; BIREN TECH (06082.HK) Jumps Nearly 20%-20260831

Mon, 31 Aug 2026 09:49:19 GMT

I. Market Overview

On August 31, 2026, Hong Kong's three major indices closed mixed, with the Hang Seng Index down 0.07%, the Hang Seng TECH Index up 0.32%, and the Hang Seng China Enterprises Index rose 0.27%. Total market turnover for the day was HKD 314.8 billion, with net southbound inflows of HKD 2.139 billion. AI concept stocks diverged on the day, with most large-model names rising and most smart-driving names weakening.

In the large-model segment, MINIMAX-W (00100.HK) closed up 16.18%, and Z.AI (02513.HK) rose 9.63%. BIDU-SW, MEITUAN-W, ALIBABA-W, and KUAISHOU-W followed the gains. TENCENT (00700.HK) closed down 0.48%.

In the AI chip segment, performance was mixed. BIREN TECH (06082.HK), whose interim-report revenue surged, jumped 18.81%, with HUA HONG GRACE, SMIC, and GIGADEVICE following the gains. MONTAGE TECHNOLOGY (06809.HK) fell 5.61%, with ILUVATAR COREX following the decline.

In the smart-driving segment, all names weakened, with BLACK SESAME (02533.HK) down 7.29%, PONY-W (02026.HK) down 5.17%, and ROBOSENSE, WERIDE-W, and HORIZONROBOT-W following the decline.

In the embodied-AI segment: UBTECH ROBOTICS (09880.HK) rose 1.56%, while XIAOMI-W (01810.HK) fell 0.72%.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
06082.HK	BIRENTECH	46.620	18.81	AI Chips
00100.HK	MINIMAX-W	349.000	16.18	LLM
02513.HK	Z.AI	1,195.000	9.63	LLM
01347.HK	HUA HONG GRACE	123.000	1.99	AI Chips
03690.HK	MEITUAN-W	78.900	1.81	LLM
09880.HK	UBTECH ROBOTICS	84.800	1.56	Embodied AI
00981.HK	SMIC	70.750	0.86	AI Chips
09888.HK	BIDU-SW	96.200	0.47	LLM
01024.HK	KUAISHOU-W	33.580	0.36	LLM
09988.HK	BABA-SW	114.200	0.26	LLM
03986.HK	GIGADEVICE	486.200	0.04	AI Chips
00700.HK	TENCENT	453.000	-0.48	LLM
09660.HK	HORIZONROBOT-W	4.720	-0.53	Autonomous Driving
01810.HK	XIAOMI-W	27.620	-0.72	Embodied AI
09903.HK	ILUVATAR COREX	388.200	-2.17	AI Chips
00800.HK	WERIDE-W	15.370	-2.72	Autonomous Driving
02498.HK	ROBOSENSE	18.060	-4.09	Autonomous Driving
02026.HK	PONY-W	55.900	-5.17	Autonomous Driving
06809.HK	MONTAGETECH	269.000	-5.61	AI Chips
02533.HK	BLACK SESAME	9.920	-7.29	Autonomous Driving

Data Source: HKEX. For reference only, not investment advice. Data as of market close on August 31, 2026.

III. AI Industry & Corporate Developments

1. CXMT's LPDDR6 memory officially enters mass production

On August 29, CXMT announced that its LPDDR6 memory has officially entered mass production. Lei Jun, founder, chairman, and CEO of Xiaomi, posted a message congratulating CXMT on achieving LPDDR6 mass production, stating that the Xuanjie O3 is the first to support CXMT's LPDDR6, and that the Xiaomi 18 Fold will be the first device to feature it.

2. a16z's Machine Age Fund raises USD 1.1 billion to invest in chips, robotics, and other hardware areas

On August 28, prominent Silicon Valley venture capital firm Andreessen Horowitz (a16z) announced that hardware has been formally established as a core direction for the firm, and raised USD 1.1 billion for its Machine Age Fund. The fund will invest in all the computing infrastructure that AI runs on, including chips, memory, networking, and storage, as well as the complete systems that run AI: from data centers to robots, and on to home AI devices. The firm noted that it has recently invested in a number of hardware companies, including Unconventional AI, Nexthop, Volta, Atoms, and Mind Robotics.

3. Tencent releases and open-sources new-generation large language model Hy4 preview

On August 28, Tencent released and open-sourced its new-generation large language model, Hy4 preview. The model has 770 billion total parameters, activates 49 billion parameters per inference, and achieves a context length of 1 million tokens. According to test results published by Tencent, Hy4 preview's performance on tasks such as programming, agent, office, and scientific research is already close to that of leading domestic open-source models.

4. BIREN TECH (06082): H1 operating revenue of RMB 1.236 billion, up nearly 2,000%

On August 28, BIREN TECH released its 2026 interim results announcement. In the first half of 2026, the company achieved operating revenue of RMB 1.236 billion, up 1,997.6% YoY; gross margin rose to 42.7%, up 1,080 basis points (bps) YoY; R&D expenses in the first half were RMB 804 million, up 40.7% YoY; the loss for the period narrowed sharply to RMB 377 million, down 76.4% YoY; and the adjusted loss for the period (a non-IFRS measure) was RMB 337 million, with the loss reduced by 38.9% YoY.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
MINIMAX-W	00100.HK	A top-tier player dedicated to omni-modal Artificial General Intelligence (AGI)	The company continuously iterates its video generation model matrix and has partnered with mainstream domestic and overseas chip manufacturers and inference platforms to complete underlying adaptations. The total monthly active users (MAU) of its B2C and B2B LLM applications, along with multimodal API call volumes, maintain rapid growth, further broadening its computing power ecological layout.
XIAOMI-W	01810.HK	Full-stack AI technology giant anchored by the "Human x Car x Home" ecosystem	Its foundational model family MiMo has entered the top tier of global open-source models; MiMo-V2-Pro features over 1 trillion parameters, while MiMo-V2.5-Pro tied for 1st globally among open-source models with a score of 54 on the Artificial Analysis composite index. AI capabilities fully power the "Human x Car x Home" ecosystem, driving iterative upgrades in the CyberOne humanoid and CyberDog bionic quadrupeds. Multimodal computer vision, force-control algorithms, and automated dispatch logics are deeply integrated into dark-factory production and flexible manufacturing.
BIRENTECH	06082.HK	China's pure-play leader in high-end general-purpose GPU (GPGPU)	Founded in 2019 and listed on the HKEX in January 2026 as the “first GPU stock in Hong Kong”, the company focuses on GPGPU chip R&D and sales, competing head‑to‑head with NVIDIA in data‑center grade AI training and inference GPUs. It has launched the BR106 and BR110 core chips and the BR166 chip co‑packaged via Chiplet technology, offering a complete solution encompassing GPGPU hardware and the BIRENSUPA software platform. Its products have been deployed across multiple domestic AI computing clusters, with the next‑generation BR20X chip planned for 2026.
HORIZONROBOT-W	09660.HK	China's leading intelligent driving computing solution provider and full‑stack vehicle intelligence enabler	Founded in 2015, it offers ADAS and high‑level autonomous driving solutions. Core products include the Journey-series in-car AI chips (cumulative shipments exceeding 10 million units), the HSD full‑scenario urban driving solution, and the "Starry 6P" cockpit‑driving integrated vehicle intelligence chip. In 2025, it held a 47.7% market share in domestic ADAS for independent brands, with full‑year revenue of RMB 3.758 billion, up 57.7% YoY.
Z.AI	02513.HK	A leading player in China's independent LLM sector	Knowledge Atlas Technology Joint Stock Company Limited (02513.HK; commercially known as Zhipu AI) is a leading player in China's independent large language model (LLM) sector (recognized for its capabilities and market position by Frost & Sullivan). The company has released its next-generation flagship model, GLM-5.2, achieving open-source State-of-the-Art (SOTA) performance in coding and agentic capabilities. It has also open-sourced the multimodal image generation model GLM-Image in collaboration with Huawei. Focusing on novel model architecture design, generalized reinforcement learning paradigms, and autonomous model evolution, its business layout closely aligns with the trend of enterprise-level AI productivity transformation.

SHANDONG XINHUA (00719.HK): Azithromycin Tablets Pass Generic Drug Consistency Evaluation

Mon, 31 Aug 2026 08:45:29 GMT

NewTimeSpace News: On 31 August 2026, Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) disclosed that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. has received the Drug Supplementary Application Approval Notice for azithromycin tablets issued by the National Medical Products Administration, with the product passing the consistency evaluation of generic drug quality and therapeutic equivalence. The product has a specification of 0.25g, acceptance number CYHB2550334 ; the application was submitted in September 2025 and approved in August 2026.

According to the announcement, azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by susceptible strains, including acute exacerbation of chronic bronchitis, community-acquired pneumonia, acute otitis media and pharyngitis. The product is a Class A item in the National Reimbursement Drug List (2025), with sales of approximately RMB 670 million in Chinese public medical institutions in 2025.

Autonomous Driving Concept Stocks Watch | BIDU-SW (09888.HK) Edges Higher in Afternoon Session, Hong Kong Primary Listing to Take Effect on September 1

Mon, 31 Aug 2026 07:48:21 GMT

NewTimeSpace News: On August 31, 2026,BIDU-SW(09888.HK) registered a mild afternoon gain. As of 15:36, its intraday price stood at HK$96.25, representing a 0.52% rise.

In related news, Baidu Group recently announced it will convert its Hong Kong listing status from secondary to primary, with the change officially effective on September 1. Upon completion, Baidu will achieve dual‑primary listing on both the Hong Kong Stock Exchange and Nasdaq.

According to Xiangcai Securities, citing Wind data, the auto sector rose 1.1% between August 24 and August 28, 2026, while the CSI 300 Index fell 0.2%. The auto sector outperformed the CSI 300 Index by 1.3 percentage points. Among the 31 Shenwan‑level sectors, the auto industry ranked 22nd in weekly performance. Year‑to‑date, the auto sector has declined 18.7%, ranking 28th out of the 31 Shenwan sectors.

BIDU-SW (09888.HK) Focuses on the R&D of L4 autonomous driving algorithms and the commercialization of unmanned Robotaxis. Leveraged by the ERNIE foundational model and optimized by the Qianfan compute base, its "Apollo Go" autonomous ride-hailing service has achieved large-scale, normalized commercial operations across multiple core cities in China, with cumulative autonomous test mileage exceeding hundreds of millions of kilometers. Through high-frequency, high-confidence real-world road test data cleansing, the company continues to solidify the most robust data asset and algorithmic moat within the HKEX autonomous driving sector.

AI Chip Concept Stocks Watch | ASMPT (00522.HK) edged up 0.12%; integrated circuit industry profit up 18.5x YoY in first seven months

Mon, 31 Aug 2026 05:52:40 GMT

NewTimeSpace (newtimespace.com) News, on August 31, 2026, the chip theme traded in a choppy session, with ASMPT (00522.HK) edging up. As of 13:47, the stock was quoted at HKD 161.100, up 0.12%.

On the news front, data disclosed by the National Bureau of Statistics shows that in January–July, profits of the electronics industry grew 1.1 times YoY, pulling up the profits of all industrial enterprises above designated size by 9.3 percentage points, and serving as the main support for the relatively rapid profit growth of industrial enterprises above designated size. Among these, the integrated circuit industry—represented by computing-power chips and memory chips—saw profits grow 18.5 times YoY, contributing more than 80% to the profit growth of the entire electronics industry.

PING AN SECURITIES noted that, driven by both the evolution of artificial intelligence technology and the need for supply-chain self-reliance and controllability, demand for advanced logic chips and high-bandwidth memory chips has grown steadily, driving a recovery in manufacturers' willingness to spend on capital expenditure. At the same time, the widespread adoption of process scaling and advanced packaging processes has further increased the equipment value per wafer manufactured, providing a favorable market environment for the sustained development of equipment companies.

Humanoid Robot Concept Stocks Watch | XIAOMI-W (01810.HK) edged down 0.58%; Europe's first humanoid robot mass-production base officially commissioned

Mon, 31 Aug 2026 05:45:28 GMT

NewTimeSpace (newtimespace.com) News, on August 31, 2026, the robotics theme fluctuated higher, while XIAOMI-W (01810.HK) weakened. As of 13:32, the stock was quoted at HKD 27.660, down 0.58%.

On the news front, on August 29, the first robot factory—jointly built by China and Serbia—officially commenced mass production. This is Europe's first humanoid robot mass-production base, marking Europe's breakthrough from zero to one in the field of scaled humanoid robot manufacturing.

SINOLINK SECURITIES noted that 2026 is an important milestone for the 0-to-1 commercialization of humanoid robots. The Tesla supply chain is expected to unveil its first-generation mass-production product within the year; as the supply chain's high-volume production line construction is completed, large-scale mass production is expected to formally commence. Shipments of leading domestic-chain robot bodies are expected to scale from several thousand units to tens of thousands of units, with application scenarios mainly coming from entertainment and commercial performances, research and education, data collection, and guiding/reception services. At this stage, leading companies' supply chains and technologies will both converge. The world will enter a robotics "arms race."

One housekeeping item: I noticed a `BOOTSTRAP.md` in your `.workbuddy` folder (workspace identity setup). I've left it untouched and focused on your translation. If you'd like, I can run that quick identity setup (name, vibe, how you want me to address you) whenever you have a moment—just say the word.

ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations

Mon, 31 Aug 2026 01:03:16 GMT

NewTimeSpace News: On 31 August 2026, Abbisko Cayman Limited (stock code: 02256) voluntarily announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd., has announced that the first patient has been dosed in the Phase I clinical trial of ABSK211, an oral, highly potent small-molecule pan-KRAS inhibitor broadly covering multiple KRAS alterations, in patients with advanced solid tumors harboring KRAS gene alterations; the study aims to evaluate the safety, tolerability, efficacy and pharmacokinetic profile of ABSK211 in these patients.

According to the announcement, KRAS is one of the most frequently altered oncogenic driver genes in human cancers, with KRAS alterations present in approximately 90% of pancreatic ductal adenocarcinoma, approximately 45% of colorectal cancer and approximately 34% of non-small cell lung cancer. Preclinical studies showed that ABSK211 exhibits broad-spectrum and potent inhibitory activity against multiple major KRAS alterations including KRAS G12D, G12C, G12S, G12V, G13D and KRAS wild-type amplification; in vitro, ABSK211 significantly inhibited the proliferation of multiple KRAS-mutant tumor cell lines at sub-nanomolar to nanomolar concentrations, with little activity against KRAS wild-type cells with normal copy numbers; in vivo studies further showed that ABSK211 induced significant and durable tumor regression in multiple KRAS-altered tumor models, with potent target engagement.

In addition, ABSK211 demonstrated favorable combination potential across multiple tumor models; when combined with PRMT5 inhibitors, cetuximab, immunotherapy and chemotherapy regimens, it further enhanced antitumor activity with potential to prolong durable responses, providing a strong basis for exploring ABSK211-based combination strategies.

ABSK211 is a novel investigational oral small-molecule pan-KRAS inhibitor independently developed by Abbisko, which has received IND approvals from both China's NMPA and the US FDA, with global clinical development advancing as planned following the first patient dosing. Abbisko, established in 2016, is a biopharmaceutical company committed to researching, discovering and developing innovative and differentiated drugs; its independently developed Class 1 new drug pimatinib has been approved for marketing by the NMPA, with dozens of other drug candidates in clinical development.

SBP GROUP (01177.HK): Kylo-11 Phase I data published in The Lancet; single dose reduces Lp(a) by up to 97% at week 48

Mon, 31 Aug 2026 00:59:58 GMT

NewTimeSpace News: On 31 August 2026,Sino Biopharmaceutical Limited (stock code: 01177) announced that the final results of the Phase I clinical study of Kylo-11 ("LPA siRNA"), a Class 1 innovative drug independently developed by its wholly-owned subsidiary Hangzhou Hejiya Biomedical Co., Ltd., were presented as a Late-Breaking Clinical Science (LBCT) oral presentation at the 2026 Congress of the European Society of Cardiology (ESC), with the full study concurrently published in The Lancet (IF: 109).

According to the announcement, the study was a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose clinical study in which 70 subjects actually received Kylo-11 or placebo. Final data showed that a single dose of Kylo-11 significantly and durably reduced Lp(a): at week 48, the median percentage reductions from baseline in Lp(a) in the mid-to-high dose groups were 94.6% in the 225 mg group (cohort 4), 95.6% in the 225 mg group (cohort 7, higher baseline group), 96.3% in the 450 mg group (cohort 5) and 97.0% in the 600 mg group (cohort 6); in cohort 7, subjects had a median baseline Lp(a) of 217.7 nmol/L, and after a single 225 mg dose, Lp(a) fell by a median absolute reduction of 207.7 nmol/L from baseline at week 48, with median Lp(a) declining to 10.5 nmol/L. In the 225 mg and above dose groups, Lp(a) approached its maximum reduction approximately 4 weeks after dosing and was maintained through week 48, providing important clinical evidence supporting the "once-a-year" dosing strategy.

In terms of safety, within 24 weeks after dosing, 37 of the 70 subjects reported adverse events, predominantly of grade 1-2, most of which were judged by investigators to be unrelated to the study drug; by the end of the 48-week study, no clear trend of increasing adverse event rates with dose was observed, and no serious adverse events, injection site reactions or deaths occurred, with Kylo-11 generally well tolerated.

Kylo-11 is a long-acting siRNA drug targeting the LPA gene, which lowers serum Lp(a) by targeting hepatic LPA mRNA and inhibiting apolipoprotein(a) synthesis; unlike conventional GalNAc-siRNA structures, Kylo-11 adopts a non-canonical siRNA molecular design with two GalNAc groups conjugated at the 3' end of the sense strand and another two GalNAc groups at the 5' end of the antisense strand. Kylo-11 is currently undergoing a Phase II clinical study in China and the United States in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a).

HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit

Mon, 31 Aug 2026 00:57:08 GMT

NewTimeSpace News: On 31 August 2026, HUTCHMED (China) Limited (stock code: 00013) announced positive topline results from the SANOVO Phase III study in China: in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations and MET overexpression, the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) versus TAGRISSO monotherapy, in both the high-MET and intent-to-treat (ITT) patient populations.

According to the announcement, in both populations, the combination also demonstrated highly encouraging overall survival (OS) clinical benefit, one of the secondary endpoints of the study; the study will continue to follow up on these results, and the data will be presented at an upcoming academic conference. The safety profile of the combination was consistent with the known safety profiles of each drug, with no new safety signals identified.

SANOVO is a blinded, randomized, controlled Phase III clinical trial that enrolled 326 treatment-naive patients with locally advanced or metastatic NSCLC harboring EGFR mutations (exon 19 deletion or L858R) and MET overexpression, randomized 1:1 to receive TAGRISSO 80 mg once daily combined with either ORPATHYS or placebo at 300/200 mg twice daily (dose depending on body weight), with investigator-assessed PFS as the primary endpoint (ClinicalTrials.gov: NCT05009836).

The announcement noted that, based on the SACHI Phase III study, the ORPATHYS and TAGRISSO combination has been approved in China for patients with EGFR-mutant locally advanced or metastatic NSCLC with MET amplification who progressed on EGFR TKI therapy; the SAFFRON global Phase III study in EGFR-mutant NSCLC patients with MET overexpression or amplification who progressed on TAGRISSO also announced positive topline results in August 2026, demonstrating statistically and clinically meaningful PFS and OS improvements. ORPATHYS was jointly developed by AstraZeneca and HUTCHMED, and is commercialized by AstraZeneca.

ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects

Sun, 30 Aug 2026 12:53:07 GMT

NewTimeSpace News: On 30 August 2026, Ascletis Pharma Inc. (stock code: 01672) voluntarily announced that the first subject has been dosed in the global Phase III clinical program of ASC30, a once-daily oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for long-term weight management. The program comprises two pivotal multicenter, randomized, double-blind, placebo-controlled Phase III trials, AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450), evaluating the long-term efficacy, safety and tolerability of ASC30 in approximately 4,600 obese or overweight subjects in the United States, Europe and Canada.

According to the announcement, both trials have a 72-week treatment period and evaluate three maintenance doses (20 mg, 40 mg and 60 mg): AURORA-1 evaluates efficacy and safety in obese subjects (BMI ≥ 30 kg/m²) or overweight subjects (BMI ≥ 27 kg/m² with at least one weight-related comorbidity) without type 2 diabetes, while AURORA-2 evaluates efficacy and safety in obese or overweight subjects (BMI ≥ 27 kg/m²) with type 2 diabetes; the primary endpoint of both trials is the percent change in body weight from baseline at week 72.

Ascletis expects to report topline data for the AURORA Phase III program in the third quarter of 2028, and expects to submit a New Drug Application (NDA) to the US FDA by the end of 2028 and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in early 2029. If approved, ASC30 has the potential to become the second oral small-molecule GLP-1 receptor agonist launched in the United States and Europe. The Company maintains a robust balance sheet and sufficient cash on hand to cover the planned regulatory submissions in the US and Europe and support operations through 2029.

In terms of pipeline, in addition to the AURORA global Phase III monotherapy program, Ascletis is also developing the first oral small-molecule GLP-1/GIP dual-target agonist fixed-dose combination similar to tirzepatide (ASC30_48FDC), the first oral small-molecule GLP-1/GIP/amylin triple-target agonist fixed-dose combination similar to tirzepatide/eloralintide (ASC30_48_39FDC), and a fixed-dose combination of oral small-molecule GLP-1 and oral amylin (ASC30_39FDC). The announcement contains a warning statement under Rule 18A.05 of the Listing Rules.

TONG REN TANG (01666.HK): Subsidiary Obtains Certificate of Registration for Chinese Patent Medicine, Sanzi Yangqin Granules to Be Sold in Hong Kong

Fri, 28 Aug 2026 13:21:06 GMT

NewTimeSpace News: On 28 August 2026, Beijing Tong Ren Tang Science & Technology Co., Ltd. (stock code: 01666) issued a voluntary announcement that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. (Tong Ren Tang Chinese Medicine), has received a Certificate of Registration of Chinese Patent Medicine issued by the Chinese Medicine Council of Hong Kong, permitting the sale of Sanzi Yangqin Granules (Tong Ren Tang) in Hong Kong. The certificate bears registration number HKC-18820 and is valid until 25 August 2031, with Tong Ren Tang Chinese Medicine registered as the holder at 3 Tai King Street, Tai Po Industrial Estate, New Territories, Hong Kong.

According to the announcement, Sanzi Yangqin Granules (Tong Ren Tang) is indicated for warming the lungs and resolving phlegm, directing qi downward and promoting digestion, for syndrome of phlegm accumulation with qi stagnation manifested as cough with wheezing and counterflow, profuse sputum with chest stuffiness, poor appetite and difficult digestion, greasy white tongue coating and slippery pulse. As of the date of the announcement, the Group's cumulative R&D investment in the product was approximately HKD 800,000 (unaudited), and the product has not yet been put on the market.

The Board stated that following the receipt of the certificate, Sanzi Yangqin Granules (Tong Ren Tang) produced by Tong Ren Tang Chinese Medicine can be sold in Hong Kong, which will enrich the Group's product line and facilitate market expansion. The receipt of the certificate is not expected to have a material impact on the Group's production, operation and results for the time being; sales of the medicine remain subject to factors including changes in the policy environment in Hong Kong, exchange rate fluctuations and market competition.

Hong Kong AI Concept Stock Daily：Xiaomi Auto's overseas website and social media accounts officially launched; AI chip sector broadly weakened-20260828

Fri, 28 Aug 2026 09:51:53 GMT

I. Market Overview

On August 28, 2026, Hong Kong's three major indices closed mixed, with AI concept stocks diverging on the day and most large-model and AI chip sectors weakening. The Hang Seng Index rose 0.07%, the Hang Seng TECH Index fell 0.33%, and the Hang Seng China Enterprises Index closed flat. The Hang Seng Index's total market turnover was HKD 231.209 billion, with net southbound inflows of HKD 1.176 billion.

In the large-model segment, the "two leaders" Z.AI (02513.HK) fell 6.03%, MINIMAX-W (00100.HK) fell 4.51%, with ALIBABA-W and KUAISHOU-W following the decline. TENCENT (00700.HK) rose 1.65%, while BIDU-SW and MEITUAN-W closed flat.

In the AI chip segment, all names weakened, with GIGADEVICE (03986.HK) down 5.81%, MONTAGE TECHNOLOGY (06809.HK) down 5.38%, and ILUVATAR COREX, HUA HONG GRACE, and SMIC following the decline.

In the smart-driving segment, most names strengthened, with PONY-W (02026.HK) up 3.97%, and WERIDE-W and BLACK SESAME following the gains. ROBOSENSE (02498.HK) fell 2.23%, and HORIZONROBOT-W closed flat.

In the embodied-AI segment, UBTECH ROBOTICS (09880.HK) closed up 0.66%, XIAOMI-W (01810.HK) rose 1.24%.

II. Market Performance of Representative AI Stocks

Stock Code	Company Name	Closing Price (HKD)	Change(%)	Sector / Concept
02026.HK	PONY-W	58.950	3.97	Autonomous Driving
00800.HK	WERIDE-W	15.800	2.27	Autonomous Driving
00700.HK	TENCENT	455.200	1.65	LLM
01810.HK	XIAOMI-W	27.820	1.24	Embodied AI
02533.HK	BLACK SESAME	10.700	1.04	Autonomous Driving
09880.HK	UBTECH ROBOTICS	83.500	0.66	Embodied AI
09888.HK	BIDU-SW	95.750	0.00	LLM
09660.HK	HORIZONROBOT-W	4.745	0.00	Autonomous Driving
03690.HK	MEITUAN-W	77.500	0.00	LLM
06082.HK	BIRENTECH	39.240	-0.05	AI Chips
01024.HK	KUAISHOU-W	33.460	-0.59	LLM
09988.HK	BABA-SW	113.900	-1.39	LLM
00981.HK	SMIC	70.150	-1.61	AI Chips
01347.HK	HUA HONG GRACE	120.600	-1.79	AI Chips
09903.HK	ILUVATAR COREX	396.800	-1.98	AI Chips
02498.HK	ROBOSENSE	18.830	-2.23	Autonomous Driving
00100.HK	MINIMAX-W	300.400	-4.51	LLM
06809.HK	MONTAGETECH	285.000	-5.38	AI Chips
03986.HK	GIGADEVICE	486.000	-5.81	AI Chips
02513.HK	Z.AI	1,090.000	-6.03	LLM

Data Source: HKEX. For reference only, not investment advice. Data as of market close on August 28, 2026.

III. AI Industry & Corporate Developments

1. Samsung Electronics, SK Hynix, and Qualcomm collaborate to advance commercialization of HBC technology

On August 26, Qualcomm executive Durga Malladi stated at Deutsche Bank's 2026 Technology Conference that Samsung Electronics and SK Hynix are actively collaborating with Qualcomm to advance the commercialization of high-bandwidth computing (HBC) technology, while continuing their respective high-bandwidth memory (HBM) R&D roadmaps. Qualcomm is responsible for compute chip design and system integration, Samsung Electronics and SK Hynix handle DRAM stacking, and they plan to work with TSMC to complete integration and packaging.

2. SMIC's H1 net profit up 94.2% YoY, driven by higher wafer shipments, ASPs, and product mix

On August 27, SMIC (688981.SH) released its 2026 interim report, posting operating revenue of RMB 38.635 billion, up 19.4% YoY; net profit attributable to shareholders of the listed company was RMB 4.467 billion, up 94.2% YoY. Among these, wafer foundry business revenue was RMB 35.858 billion, up 18.1% YoY. The profit growth was mainly attributable to increased wafer shipments, higher average selling prices, and product mix changes in the current period.

3. Profits of industrial enterprises above designated size nationwide grew 17.6% in the first seven months; integrated circuit industry profits surged 18.5x YoY

Data released by the National Bureau of Statistics on August 27 shows that in January–July, industrial enterprises above designated size nationwide achieved total profits of RMB 4,582.06 billion, up 17.6% YoY. By industry, the integrated circuit industry — represented by computing-power chips and memory chips — saw profits grow 18.5 times YoY, while the optical fiber manufacturing, optical cable manufacturing, and communications system equipment manufacturing industries posted profit growth of 468.4%, 62.6%, and 55.0%, respectively.

4. Xiaomi Auto's overseas website and social media accounts officially launched on August 26

News on August 28: Xiaomi Auto's overseas website and social media accounts were officially launched on August 26. In addition to showcasing models such as the SU7, SU7 Ultra, and Xiaomi Pengcheng Skynomad on the overseas website homepage, Xiaomi Auto also displayed the Xiaomi Vision Gran Turismo, a pure-electric smart concept supercar specially built for the GT simulation driving platform.

IV. Profiles of Representative AI Concept Stocks

Company Name	Stock Code	Industry Position	Main Product Lines & Business Overview
TENCENT	00700.HK	An Internet tech giant with a national-scale application ecosystem and the platform provider with the broadest LLM implementation scenarios in China	The Hunyuan LLM ranks highly in evaluations on third-party platforms such as OpenRouter. The model continues to deepen its integration into national-level social applications, Tencent Meeting, and the cloud-based collaborative office ecosystem. Backed by a massive MAU base and the Tencent Cloud intelligent computing service system, the company is accelerating the delivery of AI solutions to B2B clients in government and finance, continuously expanding enterprise-level application scenarios.
XIAOMI-W	01810.HK	Full-stack AI technology giant anchored by the "Human x Car x Home" ecosystem	Its foundational model family MiMo has entered the top tier of global open-source models; MiMo-V2-Pro features over 1 trillion parameters, while MiMo-V2.5-Pro tied for 1st globally among open-source models with a score of 54 on the Artificial Analysis composite index. AI capabilities fully power the "Human x Car x Home" ecosystem, driving iterative upgrades in the CyberOne humanoid and CyberDog bionic quadrupeds. Multimodal computer vision, force-control algorithms, and automated dispatch logics are deeply integrated into dark-factory production and flexible manufacturing.
PONY-W	02026.HK	Global commercialization leader in L4 autonomous mobility and logistics	The first autonomous driving company in China to secure fully driverless Robotaxi commercial operation permits across all four top-tier cities (Beijing, Shanghai, Guangzhou, Shenzhen). Core operations span autonomous ride-hailing (Robotaxi) and freight services (Robotruck), with Robotaxi deployments across 9 countries and public operations in overseas markets including Croatia, Qatar, Singapore, and South Korea. Targeting a global fleet exceeding 3,000 vehicles across 20+ cities by 2026, the company has achieved positive unit economics per vehicle.
WERIDE-W	00800.HK	The world's only L4 cross-scenario autonomous driving platform holding permits across seven countries	Holds autonomous driving permits across China, the UAE, Singapore, France, Saudi Arabia, Belgium, and the US. Built upon the proprietary WeRide One platform, the company covers smart mobility, logistics, and sanitation across five core product lines: Robotaxis, Robobuses, Robosweepers, Robovans, and Advanced Driving Assistance Systems (ADAS). Operations cover over 30 cities across 11 countries, supported by an L4 fleet exceeding 1,500 vehicles.
UBTECH ROBOTICS	09880.HK	The purest humanoid robot stock in Hong Kong	The company focuses on humanoid robot R&D, full‑stack motion control algorithms, and commercial deployment across industrial and logistics scenarios. Its flagship Walker S series has been integrated into assembly lines of leading new energy vehicle manufacturers for parts handling, precision assembly, and intelligent quality inspection, pioneering the transition from lab prototypes to industrial automation at scale.

CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China

Fri, 28 Aug 2026 09:45:33 GMT

NewTimeSpace News: On 28 August 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) announced that the Phase II clinical trial (SYH2069-004) of SYH2069 Injection, developed by the Group for weight management in overweight or obese adult patients, had been officially launched at the first study site in China.

The product is a novel long-acting dual-target dual-biased agonist of GLP-1R and GIPR, expected to synergistically exert glucose-lowering and weight-reducing effects by suppressing appetite, delaying gastric emptying, increasing satiety and reducing caloric intake. The Group obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration in December 2025 for this indication.

The Phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel clinical trial designed to evaluate the efficacy and safety of the product in obese participants without diabetes, and participant recruitment and screening are being actively advanced.

SBP GROUP (01177.HK): LM-364 "Nectin-4ᵀᴹᴱ ADC" Obtains Clinical Trial Approvals from NMPA and FDA, Accelerating Global Clinical Development

Fri, 28 Aug 2026 09:42:06 GMT

NewTimeSpace News: On 28 August 2026, Sino Biopharmaceutical Limited (stock code: 01177) announced that LM-364 "Nectin-4ᵀᴹᴱ ADC", a national Class 1 innovative drug independently developed by LaNova Medicines (Shanghai) Co., Ltd., a wholly-owned subsidiary of the Group, had obtained implied clinical trial approval from the National Medical Products Administration (NMPA) of China, intended for the treatment of advanced solid tumors. The drug obtained clinical trial approval from the U.S. FDA in April this year and officially initiated clinical trials in Australia, and the Group is accelerating its global clinical development.

According to the announcement, LM-364 is a next-generation Nectin-4 ADC developed on LaNova Medicines' proprietary tumor microenvironment (TME)-responsive ADC platform, designed to circumvent the on-target/off-target toxicity common in traditional ADCs. Preclinical data disclosed at the 2026 AACR Annual Meeting showed significant tumor inhibition across multiple PDX models, with tumor growth inhibition (TGI) of 119.1% in triple-negative breast cancer and 168.79% in cervical cancer, and a highest non-severely toxic dose (HNSTD) of 60 mg/kg in cynomolgus monkeys.

Based on the approval, the Group will evaluate the safety, tolerability and preliminary antitumor activity of LM-364 as monotherapy and in combination in patients with advanced solid tumors, and explore the recommended dose for subsequent clinical development.

SHANDONG XINHUA (00719.HK): Dapoxetine Hydrochloride Tablets Obtain Drug Registration Certificate, Enriching Formulation Portfolio

Fri, 28 Aug 2026 09:22:23 GMT

NewTimeSpace News: On 28 August 2026, Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719) announced that it had recently received the Drug Registration Certificate for Dapoxetine Hydrochloride Tablets, approved by the National Medical Products Administration, with approval number Guoyao Zhunzi H20265706, certificate number 2026S03108 and acceptance number CYHS2501422.

According to the announcement, the product is in tablet form with a specification of 30 mg (calculated as C21H23NO), classified as a prescription drug under Chemical Drug Category 4, with the application for domestic drug registration. Shandong Xinhua submitted the registration application for domestic manufacturing and marketing approval to the Center for Drug Evaluation of the National Medical Products Administration in April 2025, and obtained the Drug Registration Certificate in August 2026.

The product is indicated for the treatment of male patients aged 18 to 64 with premature ejaculation (PE) who meet all specified conditions, including an intravaginal ejaculation latency time of less than two minutes and significant personal distress or interpersonal difficulty resulting from PE. According to relevant statistics, sales of dapoxetine in Chinese public medical institutions in 2025 amounted to approximately RMB 1.03 billion.

The Company stated that the Drug Registration Certificate will further enrich its formulation product portfolio and enhance market competitiveness, while cautioning that drug sales are subject to uncertainties arising from policy changes, tendering and procurement, and market conditions in the domestic pharmaceutical industry.

Autonomous Driving Concept Stocks Watch | RoboSense (02498.HK): Afternoon Weakness, H1 LiDAR Shipments Hit 719,200 Units, Surge 169.6% YoY

Fri, 28 Aug 2026 07:28:54 GMT

NewTimeSpace News: On August 28, 2026, RoboSense (02498.HK) fell in the afternoon session. As of 15:17, it traded at HK$18.87, representing a decline of 2.02%.

According to 21st Century Business Herald, RoboSense recorded total revenue of RMB1.02 billion in the first half of 2026, rising 30.2% year‑on‑year. Total LiDAR shipments reached 719,200 units, a year‑on‑year increase of 169.6%. Among them, ADAS LiDAR shipments stood at 436,600 units, up 98.0% YoY; LiDAR shipments for robotics and other sectors totalled 282,600 units, jumping 510.4% compared with the same period last year.

AIJIAN Securities noted that capital‑raising activities of leading unmanned mining truck players are accelerating, while overseas roll‑out of turnkey solutions unlocks incremental market space. On August 17, Sany Group shipped its first batch of pure‑electric unmanned mining trucks to South America, marking the first‑ever Chinese unmanned mining truck project landing in Latin America. The project represents an upgrade from single‑equipment exports to comprehensive turnkey solutions covering vehicle fleets, dispatching systems and operation‑maintenance services. Suppliers with mass‑production and overseas delivery capabilities will be primary beneficiaries.

AI Chip Concept Stocks Watch | SMIC (688981.SH) fluctuated lower by 0.63%, with H1 2026 net profit up 94.2% YoY

Fri, 28 Aug 2026 05:32:25 GMT

NewTimeSpace (newtimespace.com) News, on August 26, 2026, the chip theme weakened, with SMIC (688981.SH) fluctuating lower. As of 13:23, the company was quoted at HK$70.850, down 0.63%.

On the news front, SMIC (688981.SH) released its 2026 interim report, recording operating revenue of RMB 38.635 billion, up 19.4% YoY; net profit attributable to shareholders of the listed company was RMB 4.467 billion, up 94.2% YoY. Among these, foundry business revenue was RMB 35.858 billion, up 18.1% YoY. The earnings growth was mainly attributable to increased wafer shipments, higher average selling prices, and changes in product mix during the period.

CAITONG SECURITIES noted that etching equipment, as a core segment of wafer manufacturing, has achieved full-process coverage from 65nm to 3nm and more advanced nodes, and has entered stable mass production at the production lines of top-tier domestic and overseas customers; meanwhile, thin-film deposition equipment such as ALD and PVD has also achieved key breakthroughs, with the product matrix continuously improving, supporting equipment makers in evolving toward a platform-based direction. As global wafer fabs expand capacity and demand for technology iteration rises, the market space for high-end equipment is expected to open up further.

Humanoid Robot Concept Stocks Watch | UBTECH ROBOTICS (09880.HK) edged up 0.24%, the "15th Five-Year Plan" clearly to accelerate cultivating "Robot+" application scenarios

Fri, 28 Aug 2026 05:22:22 GMT

NewTimeSpace (newtimespace.com) News, on August 28, 2026, the robotics theme weakened amid volatility, while UBTECH ROBOTICS (09880.HK) rose marginally against the trend. As of 13:11, the company was quoted at HK$83.150, up 0.24%.

On the news front, recently at a press conference held by the Ministry of Industry and Information Technology (MIIT) at the State Council Information Office, it was made clear that smart robots will be designated as an emerging pillar industry under the "15th Five-Year Plan," and it was proposed to accelerate the cultivation of major application scenarios such as "Robot+." On August 28, the National Development and Reform Commission (NDRC) stated it will focus on being pragmatic and effective with tangible outcomes, using embodied-intelligence training grounds and application pilot-testing bases as the lever, so that robots can iterate their technology in real scenarios and form an application closed loop around real needs.

SINOLINK SECURITIES noted that 2026 is a pivotal milestone for the humanoid robot sector to deliver on its 0-to-1 commercialization potential. The Tesla supply chain is expected to unveil its first-generation mass-produced product within the year, and as the supply chain's high-volume production lines are completed, large-scale mass production is expected to formally begin. Leading domestic robot-body makers' shipment scale is expected to jump from several thousand units to tens of thousands of units, with application scenarios mainly stemming from entertainment and commercial performances, R&D and education, data collection, and tour-guiding/sales assistance. At this stage, leading companies' supply chains and technologies will both tend to converge.

HUTCHMED (00013.HK): ATLED (Fanregratinib) Approved by NMPA for FGFR2 Fusion Cholangiocarcinoma

Fri, 28 Aug 2026 00:34:25 GMT

NewTimeSpace News: On 28 August 2026, HUTCHMED (China) Limited (stock code: 00013) announced that the new drug application for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma harbouring FGFR2 fusions or rearrangements who have received prior systemic therapy. The drug will be marketed in China under the brand name ATLED.

According to the announcement, the approval is based on data from the Phase II registration cohort of a single-arm, multi-centre, open-label Phase II/IIIb pivotal trial conducted in China (NCT04353375), which met its primary endpoint with an objective response rate of 42.5% as assessed by an independent review committee, a median progression-free survival of 6.9 months and a median overall survival of 16.6 months. Intrahepatic cholangiocarcinoma accounts for approximately 8.2%-15.0% of primary liver cancers with a five-year overall survival rate of approximately 9%, and approximately 10%-15% of global patients harbour FGFR2 fusions or rearrangements. Patient enrolment in the confirmatory Phase IIIb cohort commenced in January 2026.

TYK MEDICINES-B (02410.HK): Dovatinib mesylate tablets (TY-9591) granted conditional approval as first-line treatment for EGFR-mutant NSCLC with CNS metastases

Thu, 27 Aug 2026 13:55:56 GMT

NewTimeSpace News: On 27 August 2026, TYK Medicines, Inc (stock code: 02410) voluntarily announced that its self-developed next-generation EGFR-TKI innovative drug, dovatinib mesylate tablets (TY-9591 tablets), has been granted conditional approval for marketing by the National Medical Products Administration (NMPA), for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, with central nervous system (CNS) metastases.

According to the announcement, dovatinib mesylate tablets are a next-generation highly selective, irreversible oral EGFR-TKI, being a differentiated deuterated innovative product derived from osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites and possesses superior pharmacokinetic characteristics, demonstrating outstanding clinical efficacy and safety advantages in patients with EGFR 19del and L858R sensitive mutations with brain metastases. The Company has established multiple monotherapy and combination therapy clinical studies around the product, comprehensively covering various segment indications of advanced NSCLC.

The announcement contains a warning statement that the Company cannot guarantee the eventual successful commercialization of dovatinib mesylate tablets, and shareholders and prospective investors should exercise caution when dealing in the Company's shares.

IMMUNEONCO-B (01541.HK): First patient dosed in Phase II trial of IMM2510 plus IMM27M as first-line treatment for advanced HCC

Thu, 27 Aug 2026 13:48:22 GMT

NewTimeSpace News: On 27 August 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541) voluntarily announced that the first patient has been dosed in the Phase II clinical trial (IMM2510-HCC-201) of IMM2510 in combination with IMM27M as first-line treatment for patients with advanced hepatocellular carcinoma (HCC), a study designed to evaluate the preliminary efficacy and safety of the combination in this patient population.

According to the announcement, since the initial investigational new drug (IND) application for the combination was submitted in 2023, its clinical development has progressed steadily: the Phase Ib trial of the combination in advanced solid tumors has determined the recommended Phase II dose (RP2D), and expansion studies are ongoing in solid tumors following prior immunotherapy failure, including esophageal squamous cell carcinoma and squamous non-small cell lung cancer. Preliminary data showed the combination was generally well tolerated; among 6 evaluable patients with esophageal squamous cell carcinoma in the dose escalation stage, 3 achieved partial response (PR), 2 had stable disease (SD) and 1 had immune-unconfirmed progressive disease (iUPD), representing an objective response rate (ORR) of 50%.

In terms of mechanisms, IMM2510 is the Group's self-developed bispecific molecule targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand 1 (PD-L1), with a monoclonal antibody-receptor fusion protein (mAb-Trap) structure; IMM27M is a next-generation cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. Given HCC's strong immunosuppressive and active angiogenesis characteristics, the combination of IMM2510 and IMM27M achieves synergistic coverage of the three targets PD-L1, VEGF and CTLA-4, aiming to significantly improve antitumor efficacy over existing first-line standard treatments and provide a promising novel treatment option for patients with advanced HCC. The announcement also contains a warning statement under Rule 18A.05 of the Listing Rules, noting that the Company cannot guarantee the successful development or eventual commercialization of the combination.